September 2012

CURRICULUM VITAE

Name Timothy James Kinsella

Office Address Department of Radiation Oncology
Physicians Office Building, Suite 130
Rhode Island Hospital
110 Lockwood Street
Providence, RI 02903

Telephone 401-444-6203 (office)

E-Mail tkinsella@lifespan.org
Timothy_Kinsella@brown.edu

Fax 401-444-5335

Education

1969	B.S., St. John Fisher College, Rochester, NY
1974	M.S., Radiation Biology, University of Rochester, Rochester, NY
1974	M.D., University of Rochester, Rochester, NY
2011	M.A. *ad eundem*, Brown University, Providence, RI

Specialty Board Certification

1977	Board Certified, American Board of Internal Medicine, No. 63103, June 1977
1979	Subspecialty Board Certified, American Board of Internal Medicine (Medical Oncology), No. 63103, June 1979
1980	Subspecialty Board Certified, American Board of Radiology (Radiation Oncology), June 1980

Training Positions Held

1974-1976	Intern and Resident, Internal Medicine, Mayo Clinic, Rochester, Minnesota
1976-1977	Clinical Fellow, Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts and Assistant in Medicine, Peter Bent Brigham Hospital, Boston, Massachusetts
1977-1979	Clinical Resident, Radiation Oncology, Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts
1979-1980	Research Fellow, Laboratory of Radiobiology, Department of Cancer Biology, Harvard School of Public Health, Boston, Massachusetts

Academic Appointments

1980-1987	Senior Investigator, Radiation Oncology Branch, DCT, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (tenure appointment, 1984)
1984-1987	Deputy Chief, Radiation Oncology Branch, DCT, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
1987-1997	Professor and Chairman, Department of Human Oncology, University of Wisconsin Medical School, Madison, Wisconsin
1987-1997	Deputy Director, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin
1989-1997	Donald W. and Margaret E. Anderson Professor of Human Oncology, University of Wisconsin Medical School, Madison, Wisconsin
1997-2007	Chairman, Department of Radiation Oncology, Case Western Reserve University School of Medicine, and Director of Radiation Oncology, University Hospitals of Cleveland Health System and the Ireland Cancer Center
2000-2008	Vincent K. Smith Chair and Professor of Radiation Oncology, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center
2008-2009	Director, Stony Brook University Cancer Center, Stony Brook University Joel Strum Kenny Professor, Departments of Medicine and Radiation Oncology Stony Brook University School of Medicine
2008-Present	Adjunct Professor, Department of Radiation Oncology, Case Western Reserve University School of Medicine
2010-Present	Research Scholar Professor, Department of Radiation Oncology, Warren Alpert Medical School of Brown University and the Rhode Island Hospital, Miriam Hospital, and Women and Infants Hospital
2010-Present	Adjunct Professor, Department of Radiation Oncology, Tufts University School of Medicine and the Tufts Medical Center

Awards

1983	U.S. Public Health Service, National Institutes of Health Special Achievement Award
1984	National Institutes of Health Award of Merit
2012	National Cancer Institute Director's Service Award

Professional Societies

American Association for Cancer Research
American Society of Clinical Oncology
American Society of Therapeutic Radiology and Oncology
Radiation Research Society

National/International Committees and Other Offices (selected)

2007 – Present	President, University Radiation Medicine Foundation, Cleveland, OH
2007 – 2012	Member, Board of Scientific Advisors, National Cancer Institute
2007 – 2011	Member, Scientific Advisory Board, Integrative Cancer Biology Program, Center for Cancer Research, Massachussetts Institute of Technology, Cambridge, MA
2004 – 2010	Member, Coordinating Committee, Integrative Cancer Biology Program, Division of Cancer Biology, National Cancer Institute
2003 – 2005	Member, Radiation Discipline Working Group, National Aeronautics and Space Administration (NASA)
2000 – 2005	Member, External Advisory Committee, Data and Safety Monitoring, American College of Surgeons Oncology Group
2002 – 2004	Member, Radiation Modifier Working Group, Division of Cancer Treatment and Diagnosis, National Cancer Institute
1995 – 2003	Member, Advisory Board to New Approaches to Brain Tumor Therapy, A CNS Consortium sponsored by the National Cancer Institute
1998 – 2001	Member, Radiation Study Section, National Institutes of Health
1997 – 2001	Member, Board of Scientific Counselors, National Cancer Institute
1993 – 1999	Member, External Advisory Board, Johns Hopkins Oncology Center, Baltimore, Maryland
1995 – 1998	Member, Extramural Advisory Board, Arizona Cancer Center, University of Arizona Medical School, Tucson, Arizona
1989 – 1995	Member, Advisory Committee on Research, Alberta (Canada) Cancer Board
1990 – 1994	Member, External Advisory Board, Sylvester Cancer Center, University of Miami, Miami, Florida

National/International Committees and Other Offices (selected) (continued)

1989 – 1994	Chairman, Chemical and Biological Modifiers Committee, Radiation Therapy Oncology Group (RTOG)
1990, May	Panel Member, NIH Consensus Development Conference on Adjuvant Therapy for Patients with Colon and Rectum Cancer
1990 – 1992	Chairman, Radiation Therapy Committee, Eastern Cooperative Oncology Group (ECOG)
1983 – 1987	Member, Radiation Study Section, National Institutes of Health
1983 – 1986	Member, Working Group on Intraoperative Radiotherapy, National Cancer Institute

Editorial Boards

2011-Present	Editor in Chief, *Frontiers in Radiation Oncology*
2010-Present	Member, Editorial Board, *Molecular Medicine Reviews*
2008-Present	Member, Editorial Board, *Journal of Oncology*
2006-Present	Member, Honorary Editorial Board, *Gene Regulation and Systems Biology*
2005-Present	Member, Editorial Advisory Board, *Current Cancer Therapy Reviews*
2004-Present	Member, Editorial Board, *Medical Hypotheses and Research*
2003-Present	Member, Editorial Board, *Cancer Therapy*
2001-Present	Associate Editor, *Cancer Research*
1996-Present	Member, Editorial Academy, *International Journal of Oncology*
1991-Present	Member, Editorial Board, *Seminars in Radiation Oncology*
2002-2011	Associate Editor, *Clinical Cancer Research*
1991-2010	Member, Editorial Board, *Radiotherapy and Oncology*
2003-2007	Associate Editor, *The Cancer Journal*
1993-2002	Member, Editorial Board, *Radiation Oncology Investigations*
1996-2000	Member, Editorial Board, *The Oncologist*
1992-1998	Editor, *International Journal of Radiation Oncology, Biology, and Physics*
1991-1996	Associate Editor, *Current Problems in Cancer*
1987-1992	Associate Editor, *International Journal of Radiation Oncology, Biology, and Physics*

Editorial Boards (continued)

1987-1992	Associate Editor, *Oncology*
1989-1992	Member, Editorial Board, *PDQ*, National Cancer Institute
1987-1990	Member, Editorial Board, *Journal of Clinical Oncology*
1984-1988	Associate Editor, *Cancer Treatment Reports*

Past Research Funding (since departure from the National Cancer Institute in October 1987)

A. **NIH, 5P30-CA14520**:University of Wisconsin Clinical Cancer Center Support; P.P. Carbone, PI; T.J. Kinsella, Senior Leader, 15% effort, 15% salary and Program Leader, 10% effort, 10% salary; 01/01/88-11/01/97; $1,585,076 annual direct cost.

B. **NIH 5-U10-CA21076**: Eastern Cooperative Oncology Group - D.C. Tormey, PI, Chairman; T.J. Kinsella, Chair, Radiation Therapy Committee, 5% effort, 5% salary; 05/01/89-04/30/94; $343,179 annual direct cost.

C. **NIH 5-PO1-CA52686**: Growth Factor Alteration of Radiation Response in Tumors, T.J. Kinsella, PI; 40% effort, 25% salary; 09/01/90-08/31/94; $556,000 annual direct cost.

D. **NIH R01-CA50595**; years 1-3: Radiation and Chemosensitization with Iododeoxyuridine. T.J. Kinsella, PI; 10% effort, 10% salary; 04/01/91-03/31/94; $165,000 annual direct cost.

E. **NCI ROP NCI-CM-07301**: Phase I and Clinical Pharmacokinetic Studies of Anticancer Agents, P.P. Carbone, M.D., Principal Investigator, T.J. Kinsella, Co-Investigator, 5% effort, 5% salary; 12/01/89-05/31/95; $315,707 annual direct cost.

F. **NIH R01-CA52692**: Electron Beam Dose Planning Using Monte Carlo Simulation, T.R. Mackie, PI; T.J. Kinsella, Co-investigator, 5% effort, 5% salary; 07/01/90-06/30/93; $352,720 annual direct cost.

G. **NIH U01 CA62491:** Phase I clinical trials of novel anti-cancer therapies. J. Stewart, P.I.; TJ Kinsella, co-investigator; 5% effort; 5% salary, 04/15/94–04/13/98; $181,000 annual direct cost.

H. **NIH UO1 CA62421**: Therapeutic studies of primary CNS malignancies in adults. M. Prados (U.C.S.F.), P.I. of consortium; T.J. Kinsella and M.P. Mehta, Project directors at U.W.; 5% effort; 0% salary 04/01/94–03/31/98; $43,243 annual direct cost.

I. **NIH RO1-CA50595**; years 4-8: Tumor cell kinetics and S-phase sensitization. T.J. Kinsella, P.I.; 20% effort, 20% salary, 04/01/94 - 3/31/98; $130,000 annual direct cost.

J. **Sparta Pharmaceuticals, Inc**: *In vivo* testing of halogenated pyrimidinone compounds. T.J. Kinsella, P.I. 07/01/93- 01/31/00; $60,000 annual direct costs.

K. **NIH SBIR - Grant R 44 CA76835**: Development of IPdR as a Radiation Sensitizing Drug. H Sands, PI; TJ Kinsella, PI; Case Western Reserve University contract 10% effort; 10% salary; 1/01/00-01/31/02; $302,000 annual direct costs; $87,252 annual direct costs of Case Western Reserve University contract.

Past Research Funding (since departure from the National Cancer Institute in October 1987) (continued)

L. **NIH R01 CA50595:** years 8-12: Radiosensitization by the Halogenated Thymidine Analogs. T.J. Kinsella, PI; 20% effort; 20% salary 4/01/98-3/31/02; $129,000 annual direct costs.

M. **NIH R01 – CA79782**: Role of DNA Mismatch Repair in FdUrd-mediated cytotoxicity. DA Boothman, PI; TJ Kinsella Co-investigator, 10% effort, 10% salary; 04/01/99 – 03/31/03, $162,000 annual direct costs.

N. **NIH R01 CA84578**: Mismatch repair defects and human tumor radiosensitization. T.J. Kinsella, P.I.; 15% effort; 15% salary 01/01/00 – 12/31/04, $151,000 annual direct costs.

O. **NIH P01 CA 48735:** Phthalocyanine Photodynamic Therapy: Mechanistic Studies. N Oleinick, PI; TJ Kinsella, Director-Project 4; Clinical Phase I (± II) Testing with the Silicon Phthalocyanine Pc 4 of PDT. 10% effort: 07/01/00 – 06/30/05: $655,000 annual direct costs for program project grant, $107,000 annual direct costs for Project 4.

P. N**CI RAID Grant #197**: IPdR, an oral prodrug for tumor radiosensitization. T.J. Kinsella, PI (11/02 – 2/06). NCI invested $1,200,000 for drug synthesis, pre-clinical toxicology, GMP testing and completion of investigator-initiated IND to the FDA. (IND awarded)

Q. **NASA (Grant# NNC06GA23G)**: *In silico* modeling and laboratory study of the role of DNA mismatch repair in processing ionizing radiation damage: estimating risks for space radiation-induced microsatellite instability carcinogenesis. T.J. Kinsella, PI; 10% effort; 09/01/06 – 08/31/08; $150,000 total costs.

R. **NIH CON 103244**: Correlative Studies for Clinical Protocol P7336: Phase I/II trial of intravenous triapine in combination with pelvic radiation. T.J. Kinsella, PI; 5% effort; 09/01/06 – 09/01/08; $38,850 total direct costs.

S. **NIH P30 CA43703 - years 8-18:** Comprehensive Cancer Center Support Grant. S. Gerson, PI; TJ Kinsella, Co-leader, Radiation and Cellular Stress Program; 10% effort: 11/01/97 - 09/01/08, $2,553,394 annual direct costs in year 18.

T. **NIH U56 CA112963:** Complex Systems and Control of MMR-deficient cells. T.J. Kinsella, PI; 30% effort: 9/01/04 – 02/28/10: $312,028 year 5 direct costs (1 year no cost extension through 2/28/11).

U. **NIH U56 CA112963:** Supplement: Developing a Systems Biology Model of Genetic/Epigenetic Signaling Networks to Predict Tumor Response to Fluoropyridine Based Radiosensitization in Rectal Cancer. T.J. Kinsella, PI; 5% effort; 10/01/07 – 02/28/11; $120,000 total direct costs.

V. N**IH R21 CA140901:** Modeling of DNA mismatch repair to improve cancer therapeutics. E. Guran-Cavusoglu PI; T.J.Kinsella, co-investigator; 10% effort; 07/01/09-06/30/11; $150,000 direct year 1 costs.

Pre-Doctoral/Post-Doctoral Research Preceptorships

1. Elizabeth M. Miller, Ph.D., pre-doctoral student, 1987-1991 - Received Ph.D. in Human Cancer Biology at the University of Wisconsin, June, 1991; Present Position: Researcher, Departments of Cytogenetics and Immunopathology, Penrose-St. Francis Health Systems, Colorado Springs, CO.

2. Christopher Schultz, M.D., post-doctoral fellow, 1990-1991; Present Position: Professor, Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI.

3. Kwan-Hwa Chi, M.D., post-doctoral fellow, 1991-1992, Present Position: Professor and Chairman, Department of Radiation Therapy and Oncology, National Yang-Ming University, Taipei, Taiwan.

4. Cornelius J. McGinn, M.D., post-doctoral fellow, 1991-1993, Present Position: Director, Department of Radiation Oncology, Maine Medical Center, Portland, ME

5. Mei-Ling Kuo, Ph.D., pre-doctoral student, 1992-1997; Received Ph.D. in Human Cancer Biology at the University of Wisconsin , June 1997. Present position: Senior Research Associate, Department of Clinical and Molecular Pharmacology, City of Hope Cancer Center, Duarte, CA.

6. Hwa-Shin Hwang, Ph.D., post-doctoral fellow, 1997-2001, Present Position: Staff Scientist, Cancer Pharmacology, Sunesis Pharmaceuticals, Emeryville, CA.

7. Pietro Taverna, Ph.D., post-doctoral fellow, 2000-2001, Present Position: Staff Scientist, Cancer Pharmacology, Sunesis Pharmaceuticals, Emeryville, CA.

8. Konstantin Leskov, Ph.D., pre-doctoral student, 1995-2001 – Received Ph.D. in Human Cancer Biology at the University of Wisconsin, December 2001; Present Position: Assistant Professor, Department of Pediatrics at Case Western Reserve University.

9. Suzanne Berry, Ph.D., pre-doctoral student, 1997-2001 - Received Ph.D. in Human Cancer Biology at the University of Wisconsin, December 2001; Present Position: Assistant Professor, Department of Genetics, School of Vetinary Medicine, University of Illinois-Champaign.

10. Tamalette Loh, Ph.D., 2001 - 2004, post-doctoral fellow in the Department of Radiation Oncology at Case Western Reserve University; Present position: Science Writer/Editor, ProEd Communications, Inc., Beachwood, OH.

11. Yuji Seo, M.D., 2002 - 2006, post-doctoral fellow in the Department of Radiation Oncology at Case Western Reserve University; Present position: Assistant Professor, Department of Radiation Oncology, Osaka University, Osaka, Japan.

12. Charles A. Kunos, M.D., Ph.D., 2004-2007, post-doctoral fellow in the Department of Radiation Oncology at Case Western Reserve University; supported on NIH grant K12 CA76917; present position: Assistant Professor, Department of Radiation Oncology, Case Western Reserve University

13. Mohammad Azhar Aziz, Ph.D., 2005 – 2008, post-doctoral fellow in the Department of Radiation Oncology at Case Western Reserve University; Present position: Principal Investigator, King Abdullah International Medical Research Center, Saudi Arabia.

14. Xuehuo Zeng, Ph.D., 2005 – 2010, post-doctoral fellow in the Department of Radiation Oncology at Case Western Reserve University.

15. Weinan Du, Ph.D., 2006 – 2011, post-doctoral fellow in the Department of Radiation Oncology at Case Western Reserve University.

BIBLIOGRAPHY

Peer-Reviewed Manuscripts

1. Kinsella TJ. The application of cellular kinetics to the radiobiology of solid tumors. Thesis for Master of Science, Department of Radiation Biology, University of Rochester School of Medicine, 1974.

2. Kinsella TJ, Ahmann DL, Guiliani ER, Lie JT. Adriamycin cardiotoxicity in stage IV breast cancer: possible enhancement with prior left chest radiation therapy. Int J Rad Oncol Biol Phys 5:1997-2002, 1979.

3. Kinsella TJ, Bloomer WD. Bowel tolerance to radiation therapy. Surg Gyn Obstet 151:273-284, 1980.

4. Kinsella TJ, Bloomer WD, Lavin PT, Knapp RC. Stage II endometrial carcinoma: ten-year follow-up of combined radiation and surgical treatment. Gynecologic Oncology 10:290-297, 1980.

5. Kinsella TJ, Malcolm AW, Bothe A, Valerio D, Blackburn GL. A prospective study of nutritional support during pelvic irradiation. Int J Rad Oncol Biol Phys 7:543-548, 1981.

6. Lokich J, Kinsella TJ, Perri J, Malcolm A, Clouse M. Concomitant hepatic radiation and intra-arterial fluorinated pyrimidine therapy: correlation of liver scan, liver function tests and plasma CEA with tumor response. Cancer 48:2569-2574, 1981.

7. Kinsella TJ, Little JB, Nove J, Weichselbaum RR, Li FP, Mayer RJ, Marchetto D, Patterson WB. Heterogenous response to x-ray and UV light irradiation of cultured skin fibroblasts in two families with Gardner's syndrome. J Natl Cancer Inst 68:697-702, 1982.

8. Pretorius HT, Katikieneni M, Kinsella TJ, Barsky S, Brennan MF, Chu E, Robbins J. Thyroid nodules following high dose radiotherapy: fine needle aspiration biopsy in diagnosis and management. JAMA 24:3217-3221, 1982.

9. Kinsella TJ, Mitchell JB, McPherson S, Russo A, Tietze F. *In vitro* x-ray sensitivity in ataxia telangiectasia homozygote and heterozygote skin fibroblasts under oxic and hypoxic conditions. Cancer Research 42:3950-3956, 1982.

10. Mitchell JB, Russo A, Kinsella TJ, Glatstein E. Glutathione elevation during thermotolerance induction and thermosensitization by glutathione depletion. Cancer Research 43:987-991, 1983.

11. Mitchell JB, Kinsella TJ, Russo A, McPherson S, Rowland J, Kornblith PL, Smith B, Glatstein E. Radiosensitization of hematopoietic precursor cells (CFU-C) in glioblastoma patients receiving intermittent intravenous infusions of bromodeoxyuridine (BUdR). Int J Rad Oncol Biol Phys 9:457-463, 1983.

12. Carney DN, Mitchell JB, Kinsella TJ. *In vitro* radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphologic variants. Cancer Research 43:2806-2811, 1983.

13. Kinsella TJ, Triche TJ, Dickman PS, Costa J, Tepper JE, Glaubiger D. Extraskeletal Ewing's sarcoma: results of combined modality treatment. J Clin Oncol 1:489-495, 1983. Note: Recent commentary of this article- 25 years later (#101 in editorials section).

Peer-Reviewed Manuscripts (continued)

14. Kinsella TJ, Loeffler JS, Fraass BA, Tepper JE. Extremity preservation by combined modality therapy in sarcomas of the hand and foot: an analysis of local control, disease-free survival and functional result. Int J Rad Oncol Biol Phys 9:1115-1119, 1983.

15. Sindelar WF, Kinsella TJ, Tepper JE, Travis EL, Rosenberg SA, Glatstein E. Experimental and clinical studies with intraoperative radiotherapy. Surgery, Gynecology, Obstetrics 157:205-219, 1983.

16. Fraass BA, Harrington FS, Kinsella TJ, Sindelar WF. Television system for verification and documentation of treatment fields during intraoperative radiation therapy. Int J Rad Oncol Biol Phys 9:1409-1411, 1983.

17. Morstyn G, Hsu S-M, Kinsella T, Gratzner H, Russo A, Mitchell JB. Bromodeoxyuridine in tumors and chromosomes detected with a monoclonal antibody. J Clin Invest 72:1844-1850, 1983.

18. Kinsella TJ, Glaubiger D, Diesseroth A, Makuch R, Waller B, Pizzo P, Glatstein E. Intensive combined modality therapy including low-dose TBI in high-risk Ewing's sarcoma patients. Int J Rad Oncol Biol Phys 9:1955-1960, 1983.

19. Kinsella TJ, Russo A, Mitchell JB, Rowland J, Jenkins J, Schwade JG, Myers CE, Collins JM, Kornblith P, Smith B, Kufta C, Glatstein E. A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) and conventional fractionated irradiation. Int J Rad Oncol Biol Phys 10:69-76, 1984.

20. Russo A, Gianni L, Kinsella TJ, Klecker RW, Jenkins J, Rowland J, Glatstein E, Mitchell JB, Collins J, Myers C. A pharmacologic evaluation of intravenous delivery of BUdR to patients with brain tumors. Cancer Res 44:1702-1705, 1984.

21. Schwade JJ, Kinsella TJ, Rowland J, Johnston M, Glatstein E. Clinical experience with intravenous misonidazole for carcinoma of the esophagus. Cancer Investigation 2:91-95, 1984.

22. Kinsella TJ, Mitchell JB, McPherson S, Triche TJ, Miser J, Glatstein E. *In vitro* radiation studies on Ewing's sarcoma cell lines and human bone marrow CFU-C: application to the clinical use of total body irradiation (TBI). Int J Rad Oncol Biol Phys 10:1005-1011, 1984.

23. Tester W, Kinsella TJ, Waller B, Makuch R. Kelley PA, Glatstein E, DeVita VT. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute Experience. J Clin Oncol 2:762-769, 1984.

24. Mitchell JB, Morstyn G, Russo A, Kinsella TJ, Fornace AJ, McPherson S, Glatstein E. Differing sensitivity to fluorescent light in Chinese hamster cells containing equally incorporated quantities of BUdR versus IUdR. Int J Rad Oncol Biol Phys 10:1447-1452, 1984.

25. Morstyn G, Kinsella TJ, Hsu S-M, Russo A, Gratzner H, Mitchell JB. Identification of bromodeoxyuridine in malignant and normal cells following therapy: relationship to complications. Int J Rad Oncol Biol Phys 10:1441-1446, 1984.

26. Kinsella TJ, Mitchell JB, Russo A, Morstyn G, Hsu S-M, Rowland J, Glatstein E. Continuous intravenous infusion of bromodeoxyuridine (BUdR) as a clinical radiosensitizer. J Clin Oncol 2:1144-1150, 1984.

Peer-Reviewed Manuscripts (continued)

27. Potter DA, Glenn J, Kinsella TJ, Glatstein E, Lack EE, Restrepo C, White DE, Seipp CA, Wesley R, Rosenberg SA. Patterns of recurrence in patients with high-grade soft tissue sarcomas. J Clin Oncol 3:353-366, 1985.

28. Glenn J, Kinsella TJ, Glatstein E, Tepper J, Baker A, Sugarbaker P, Sindelar W, Roth J, Brennan M, Costa J, Seipp C, Wesley R, Young RC, Rosenberg S. A randomized prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast and trunk. Cancer 55:1206-1214, 1985.

29. Glenn J, Sindelar WF, Kinsella TJ, Glatstein E, Tepper J, Costa J, Baker A, Sugarbaker P, Brennan MF, Seipp C, Wesley R, Young RC, Rosenberg SA. Results of multimodality therapy of resectable soft-tissue sarcomas of the retroperitoneum. Surgery 97:316-325, 1985.

30. Fraass BA, Kinsella TJ, Harrington FS, Glatstein E. Peripheral dose to the testes: the design and clinical use of a practical and effective gonadal shield. Int J Rad Oncol Biol Phys 11:609-615, 1985.

31. Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, McCoy WM, Young RC, Ozols RF. Radiation survival parameters of antineoplastic drug-sensitive and resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Research 45:2110-2115, 1985.

32. Fraass BA, Miller RW, Kinsella TJ, Sindelar WF, Harrington FS, van de Geijn J, Glatstein E. Intraoperative radiation therapy at the National Cancer Institute: technical innovations and dosimetry. Int J Rad Oncol Biol Phys 11:1299-1312, 1985.

33. Tochner ZA, Kinsella TJ, Glatstein E. Hepatic irradiation in the management of metastatic hormone-secreting tumors. Cancer 56:20-24, 1985.

34. Morstyn G, Kinsella T, Shan, Chien Song Kao, Whang-Peng J, Russo A, Mitchell JB. *In vivo* incorporation of bromodeoxyuridine into proliferating cells in the marrow and its effects on granulocyte-macrophage progenitor cells. Experimental Hematology 13:289-294, 1985.

35. Klecker RW, Jenkins JF, Kinsella TJ, Fine RL, Strong JM, Collins JM. Clinical pharmacology of 5-iodo-2'-deoxyuridine and 5-iodouracil, and endogenous pyrimidine modulation. Clinical Pharmacology and Therapeutics 38:45-51, 1985.

36. Shapiro E, Kinsella TJ, Makuch R, Fraass BA, Glatstein E, Rosenberg SA, Sherins RJ. The effects of fractionated irradiation on testicular function. J Clin Oncol 3:1232-1239, 1985.

37. Kinsella TJ, Sindelar WF, DeLuca AM, Pezeshkpour G, Smith R, Kranda K, Mixon A, Yeakel K, Miller R. Tolerance of peripheral nerve to intraoperative radiotherapy (IORT): clinical and experimental studies. Int J Rad Oncol Biol Phys 11:1579-1585, 1985.

38. Kinsella TJ, Russo A, Mitchell JB, Collins JR, Rowland J, Wright D, Glatstein E. Phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer. Int J Rad Oncol Biol Phys 11:1941-1946, 1985.

39. Mitchell JB, Karawya E, Kinsella TJ, Wilson SH. Measurement of DNA polymerase B in skin fibroblast cell lines from patients with ataxia telangiectasia. Mutation Research 146:295-300, 1985.

40. Fornace AJ Jr, Kinsella TJ, Dobson P, Mitchell JB. Repair of ionizing radiation DNA base damage in ataxia telangiectasia cells. Cancer Research 46:1703-1706, 1986.

Peer-Reviewed Manuscripts (continued)

41. Potter DA, Kinsella TJ, Glatstein E, Wesley R, White DE, Seipp CA, Lack EE, Costa J, Rosenberg SA. High-grade soft tissue sarcomas of the extremities. Cancer 58:190-205, 1986.

42. Fornace AJ Jr, Dobson P, Kinsella TJ. Repair of x-ray induced DNA base damage in xeroderma pigmentosum cells. Radiation Research 106:73-76, 1986.

43. Fornace AJ Jr, Dobson P, Kinsella TJ. Analysis of the effect of DNA alkylation on alkaline elution. Carcinogenesis 7:927-932, 1986.

44. Kinsella TJ, Dobson P, Russo A, Mitchell JB, Fornace AJ Jr. Modulation of x-ray DNA damage by SR-2508 + buthionine sulfoximine. Int J Rad Oncol Biol Phys 12:1127-1130, 1986.

45. Kinsella TJ, Dobson P, Mitchell JB. Interaction of iododeoxyuridine (IdUrd) and its primary metabolite, iodouracil (IUra) on radiation response. Int J Rad Oncol Biol Phys 12:1519-1522, 1986.

46. Russo A, DeGraff W, Kinsella TJ, Gamson J, Glatstein E, Mitchell JB. Potentiation of chemotherapy cytotoxicity following iododeoxyuridine incorporation of Chinese hamster cells. Int J Rad Oncol Biol Phys 12:1371-1374, 1986.

47. Tepper JE, Gunderson LL, Goldson AL, Kinsella TJ, Shipley WH, Sindelar WF, Wood WC, Martin JK. Quality control parameters of intraoperative radiation therapy. Int J Rad Oncol Biol Phys 12:1687-1695, 1986.

48. Belanger K, Klecker R, Rowland J, Kinsella TJ, Collins JM. Incorporation of iododeoxyuridine (IdUrd) into cellular DNA in patients receiving continuous intravenous infusions. Cancer Res 46:6509-6512, 1986.

49. Sindelar WF, Hoekstra H, Restrepo C, Kinsella TJ. Pathological tissue changes following intraoperative radiotherapy. Am J Clin Oncol 9:504-509, 1986.

50. Kinsella TJ, Glatstein E. Clinical experience with intravenous radiosensitizers in unresectable sarcomas. Cancer 59:908-915, 1987.

51. Barnes M, Pass H, DeLuca A, Tochner Z, Potter D, Terrill R, Sindelar WF, Kinsella TJ. Response of the mediastinal and thoracic viscera of the dog to intraoperative radiation therapy (IORT). Int J Rad Oncol Biol Phys 13:371-378, 1987.

52. Kinsella TJ, Dobson PP, Mitchell JB, Fornace AJ. Enhancement of x-ray induced DNA damage by pretreatment with halogenated pyrimidine analogs. Int J Rad Oncol Biol Phys 13:733-739, 1987.

53. Pass HI, Sindelar WF, Kinsella TJ, DeLuca AM, Barnes M, Kurtzman S, Hoekstra H, Tochner Z, Roth J, Glatstein E. Delivery of intraoperative radiation therapy (IORT) after pneumonectomy: experimental observations and early clinical results. Ann Thor Surg 44:14-20, 1987.

54. McKenna WG, Barnes M, Kinsella TJ, Rosenberg SA, Lack EE, Glatstein EJ. Combined modality treatment of adult soft tissue sarcomas of the head and neck. Int J Rad Oncol Biol Phys 13:1127-1134, 1987.

55. Miller RW, DeGraff W, Kinsella TJ, Mitchell JB. Evaluation of incorporated iododeoxyuridine cellular radiosensitization by photon activation therapy. Int J Rad Oncol Biol Phys 13:1193-1198, 1987.

Peer-Reviewed Manuscripts (continued)

56. Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, Wesley R, Magrath I. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5:1191-1198, 1987.

57. Jackson D, Kinsella TJ, Rowland J, Wright D, Katz D, Main D, Collins J, Kornblith P, Glatstein E. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme. Amer J Clin Oncol 10:437-443, 1987.

58. Stea B, Kinsella TJ, Triche TJ, Horvath K, Glatstein E, Miser JS. Treatment of pelvic sarcomas in adolescents and young adults with intensive combined modality therapy. Int J Rad Oncol Biol Phys 13:1797-1806, 1987.

59. Miser JS, Kinsella TJ, Triche TJ, Steis R, Tsokos M, Wesley R, Horvath K, Belasco J, Longo D, Glatstein E, Israel MA. Treatment of peripheral neuroepithelioma in children and young adults. J Clin Oncol 5:1752-1758, 1987.

60. Kinsella TJ, Dobson PP, Fornace AJ Jr, Barrett SF, Ganges MB, Robbins JH. Alzheimer's disease fibroblasts have normal repair of N-methyl-N'-nitro-N-nitrosoguanidine induced DNA damage determined by the alkaline elution technique. Biochem Biophys Res Comm 149:355-361, 1987.

61. Kinsella TJ, Miser JS, Triche TJ, Horvath K, Glatstein E. Treatment of "high risk" sarcomas in children and young adults: analysis of local control using intensive combined modality therapy. NCI Monograph 6:291-296, 1988.

62. Kinsella TJ, Sindelar WF, Lack E, Glatstein E, Rosenberg SA. Preliminary results of a randomized study of adjuvant radiation therapy in resectable adult retroperitoneal soft tissue sarcomas. J Clin Oncol 6:18-25, 1988.

63. Hoekstra HJ, Restrepo C, Kinsella TJ, Sindelar WF. Histopathological effects of intraoperative radiotherapy on pancreas and adjacent tissues: a postmortem analysis. J Surg Oncol 37:104-108, 1988.

64. Sindelar WF, Hoekstra HJ, Kinsella TJ. Surgical approaches and techniques in intraoperative radiotherapy for intra-abdominal, retroperitoneal and pelvic neoplasms. Surgery 103:247-256, 1988.

65. Kinsella TJ, Sindelar WF, DeLuca AM, Barnes M, Tochner Z, Mixon A, Glatstein E. Tolerance of the canine bladder to intraoperative radiation therapy: an experimental study. Int J Rad Oncol Biol Phys 14:939-946, 1988.

66. Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Forquer R, Wesley R, Horvath K, Belasco J, Longo D, Steis R, Glatstein E, Pizzo PA. Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality therapy without maintenance. J Clin Oncol 6:484-496, 1988.

67. Kinsella TJ, Collins J, Rowland J, Klecker R, Wright D, Katz D, Steinberg SM, Glatstein E. Pharmacology and Phase I/II study of continuous intravenous infusions of iododeoxyuridine (IdUrd) and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol 6:871-879, 1988.

68. Speth PAJ, Kinsella TJ, Belanger K, Klecker RW Jr, Smith R, Rowland J, Collins JM. Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: A Phase I and clinical pharmacological study. Cancer Res 48:2933-2937, 1988.

Peer-Reviewed Manuscripts (continued)

69. Sindelar WF, Hoekstra HJ, Kinsella TJ, Barnes M, DeLuca PM, Tochner Z, Pass HI, Kranda KC, Terrill RE. Response of the canine esophagus to intraoperative electron beam radiotherapy. Int J Radiat Oncol Biol Phys 15:663-670, 1988.

70. Hoekstra HJ, Sindelar WF, Kinsella TJ. Surgery with intraoperative radiotherapy for sarcomas of the pelvic girdle. Int J Rad Oncol Biol Phys 15:1013-1016, 1988.

71. Chang AE, Kinsella TJ, Glatstein E, Baker AR, Sindelar WF, Lotze MT, Danforth DN, Sugarbaker PH, Lack EE, Steinberg SM, White DE, Rosenberg SA. Adjuvant chemotherapy for patients with high grade soft tissue sarcomas of the extremity. J Clin Oncol 6:1491-1500, 1988.

72. Stea B, Cavazzana A, Kinsella TJ. Small cell osteosarcoma: correlation of *in vitro* and clinical radiation response. Int J Radiat Oncol Biol Phys 15:1233-1238, 1988.

73. Speth PAJ, Kinsella TJ, Chang AE, Klecker RW, Belanger K, Collins JM. Selective incorporation of iododeoxyuridine into DNA of hepatic metastases versus normal human liver. Clin Pharmacol Therapeutics 44:369-375, 1988.

74. Young MM, Kinsella TJ, Miser JS, Triche TJ, Steinberg SM, Glatstein E. Treatment of sarcomas of the chest wall using intensive combined modality therapy. Int J Radiat Oncol Biol Phys 16:49-57 1989.

75. Speth PA, Kinsella TJ, Chang AE, Klecker K, Cupp JE, Collins JM. Iododeoxyuridine (IdUrd) incorporation into DNA of human hematopoietic cells, normal liver and hepatic metastases in man as a radiosensitizer and as a marker for cell kinetic studies. Int J Radiat Oncol Biol Phys 16:1247-1250, 1989.

76. Mehta MP, Goetowski PG, Kinsella TJ. Radiation-induced thyroid neoplasms, 1920-1987, a vanishing problem. Int J Radiat Oncol Biol Phys 16:1471-1475, 1989.

77. Kinsella TJ, Trivette G, Rowland J, Sorace R, Miller R, Fraass B, Steinberg SM, Glatstein E, Sherins RJ. Long term follow-up of testicular function following radiation therapy for early stage Hodgkin's disease. J Clin Oncol 6:718-724, 1989.

78. Chang AE, Collins JM, Speth PAJ, Smith R, Walton L, Begley MG, Glatstein E,, Kinsella TJ. A Phase I study of intra-arterial iododeoxyuridine in patients with colorectal liver metastases. J Clin Oncol 7:662-668, 1989.

79. Tochner Z, Kinsella TJ, Rowland J, Glatstein E. Treatment of unresectable sarcomas of adults with hyperfractionated irradiation and iododeoxyuridine. British I of Radiology 19:107-111, 1989.

80. Hoekstra HJ, Sindelar WF, Kinsella TJ, Mehta DM. Intraoperative radiation therapy-induced sarcomas in dogs. Radiation Res 120:508-515, 1989.

81. Cromack DT, Maher MM, Hoekstra H, Kinsella TJ, Sindelar WF. Are complications in intraoperative radiation therapy more frequent than in conventional treatment? Arch Surg 124:229-234, 1989.

82. Lack EE, Steinberg SM, White DE, Kinsella TJ, Glatstein E, Chang AE, Rosenberg SA. Extremity soft tissue sarcomas: analysis of prognostic variables with emphasis on reproducibility of tumor typing and grading. J Surg Oncol 41:263-273, 1989.

Peer-Reviewed Manuscripts (continued)

83. Mehta MP, Shahabi S, Jarjour NN, Kinsella TJ. Endobronchial irradiation for malignant airway obstruction. Int J Radiat Oncol Biol Phys 17:847-851, 1989.

84. Bader JL, Horowitz ME, Dewan R, Watkins E, Triche TJ, Tsokos M, Kinsella TJ, Miser JS, Steinberg SM, Glatstein E. Intensive combined modality therapy of small round cell and undifferentiated sarcomas in children and young adults: Local control and patterns of failure. Radiotherapy and Oncology 16:189-201, 1989.

85. Oldfield EH, Friedman R, Kinsella TJ, Moquin R, Yeakle K, DeLuca AM. Reduction in radiation-induced brain injury by use of pentobarbital or lidocaine protection. J Neurosurgery 72:737-744, 1990.

86. Fornace AJ, Dobson PP, Kinsella TJ. Enhancement of radiation damage in cellular DNA following unifilar substitution with iododeoxyuridine. Int J Radiat Oncol Biol Phys 18:873-878, 1990.

87. Kunugi KA, Vazquez-Padua MA, Miller EM, Kinsella TJ. Modulation of IdUrd-DNA incorporation and radiosensitization in human bladder carcinoma cells. Cancer Research 50:4962-4967, 1990.

88. Shanahan TG, Mehta MP, Bertelrud KL, Buchler DA, Frank LE, Gehring MA, Kubsad SS, Utrie PC, Kinsella TJ. Minimization of small bowel volume within treatment fields utilizing customized "belly boards". Int J Radiat Oncol Biol Phys 19:469-476, 1990.

89. Mehta M, Shahabi S, Thomadsen B, Uehling D, Kinsella TJ. A three-dimensional model for treatment planning of interstitial implants. Endocurie, Hypertherm, Oncol 5:227-230, 1990.

90. Mehta MP, Kubsad SS, Fowler JF, Verma AK, Hsieh J-T, Kinsella TJ. ^{90}Y-B72.3 against pancreatic cancer: Therapeutic, dosimetric and biological analyses. Int J Radiat Oncol Biol Phys 19:627-632, 1990.

91. Barnes M, Duray P, DeLuca A, Anderson W, Sindelar W, Kinsella T. Tumor induction following intraoperative radiotherapy: Late results of the National Cancer Institute canine trials. Int J Radiat Oncol Biol Phys 19:651-660, 1990.

92. Kubsad SS, Mackie TR, Gehring MA, Misisco DJ, Paliwal BR, Mehta MP, Kinsella TJ. Monte Carlo and convolution dosimetry for stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 19:1027-1035, 1990.

93. Hartman KR, Triche TJ, Kinsella TJ, Miser JS. Prognostic value of histopathology in Ewing's sarcoma: Long-term follow-up of distal extremity primary tumors. Cancer 76:163-171, 1990.

94. Kinsella TJ, Miser JA, Waller B, Venzon D, Glatstein E, Weaver-McClure L, Horowitz ME. Long term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys 20:389-395, 1991.

95. Kinsella TJ, DeLuca AM, Barnes M, Anderson W, Terrill R, Sindelar WF. Threshold dose for peripheral nerve injury following intraoperative radiotherapy (IORT) in a large animal model. Int J Radiat Oncol Biol Phys 20:697-701, 1991.

96. Rozental JM, Levine RL, Mehta MP, Kinsella TJ, Levin AB, Algan O, Mendoza M, Hanson JM, Schrader DA, Nickles RJ. Early changes in tumor metabolism after treatment: The effects of stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 20:1053-1060, 1991.

Peer-Reviewed Manuscripts (continued)

97. Gehring MA, Mackie TR, Kubsad SS, Paliwal BR, Mehta MM, Kinsella TJ. A three dimensional volume visualization package applied to stereotactic radiosurgery treatment planning. Int J Radiat Oncol Biol Phys 21:491-500, 1991.

98. Rodriguez R, Miller E, Fowler JF, Kinsella TJ. Continuous infusion of halogenated pyrimidines. Int J Radiat Oncol Biol Phys 20:1380-1381, 1991.

99. Tochner ZA, Pass HI, Sindelar WF, DeLuca AM, Grisell DL, Bacher JD, Kinsella TJ. Long term tolerance of thoracic organs to intraoperative radiotherapy. Int J Radiat Oncol Biol Phys 22:65-69, 1991.

100. Miller EM, Kinsella TJ. Radiosensitization by fluorodeoxyuridine: Effects of thymidylate synthase inhibition and cell synchronization. Cancer Res 52:1687-1694, 1992.

101. Tsokos M, Webber B, Parham D, Wesley R, Miser A, Miser JS, Etcubanas E, Kinsella T, Grayson J, Glatstein E, Triche TJ. Rhabdomyosarcoma: A new classification scheme related to prognosis. Archives Pathology and Laboratory Medicine 116:847-855, 1992.

102. Ritter MA, Messing EM, Shanahan TG, Chappell RJ, Kinsella TJ. Prostate-specific antigen (PSA) as a predictor of radiotherapy response and of patterns of failure in localized prostate cancer. J Clin Oncology 10:1208-1217, 1992.

103. Mehta M, Petereit D, Harmon M, Fowler J, Shahabi S, Thomadsen B, Kinsella T. Sequential comparison of low dose rate and hyperfractionated high dose rate endobronchial radiation for malignant airway occlusion. Int J Radiat Oncol Biol Phys 23:133-139, 1992.

104. Miller EM, Fowler JF, Kinsella TJ. Linear quadratic analysis of radiosensitization by halogenated pyrimidines: I. Radiosensitization of human colon cancer cells by IUdR. Radiation Res 131:81-89, 1992.

105. Miller EM, Fowler JF, Kinsella TJ. Linear quadratic analysis of radiosensitization by halogenated pyrimidines: II. Radiosensitization of human colon cancer cells by BUdR. Radiation Res 131:90-97, 1992.

106. Ritter MA, Fowler JF, Kim Y, Lindstrom MJ, Kinsella TJ. Single biopsy, tumor kinetic analyses: A comparison of methods and an extension to shorter sampling intervals. Int J Radiat Oncol Biol Phys 23:811-820, 1992.

107. Stitt JA, Fowler JF, Thomadsen BR, Buchler DA, Paliwal BP, Kinsella TJ. High dose rate intracavitary brachytherapy for carcinoma of the cervix: The Madison system. I. Clinical and radiobiological considerations. Int J Radiat Oncol Biol Phys 24:335-348, 1992.

108. Thomadsen BR, Stitt JA, Fowler JF, Buchler DA, Paliwal BP, Kinsella TJ. High dose rate intracavitary brachytherapy for carcinoma of the cervix: The Madison system. II. Procedural and physical considerations. Int J Radiat Oncol Biol Phys 24:349-358, 1992.

109. Kunugi KA, Miller EM, Vazquez-Padua MA, Kinsella TJ. Low pH does not affect the dose-response for 5'-amino-5'-deoxythymidine modulation of IdUrd DNA-incorporation and radiosensitization in a human bladder cancer cell line. Radiation Res 132:222-227, 1992.

110. Mehta MP, Rozental JM, Levin AV, Mackie TR, Kubsad SS, Gehring MA, Kinsella TJ: Defining the role of radiosurgery in the management of brain metastases. Int J Radiat Oncol Biol Phys 24:619-625, 1992.

Peer-Reviewed Manuscripts (continued)

111. McGinn CJ, Stitt JA, Buchler DA, Kinsella TJ. Intraoperative ultrasound guidance during high dose rate intracavitary brachytherapy of the uterine cervix and corpus. Endo/Hyper Onc 8:101-104, 1992.

112. Petereit DG, Mehta MP, Buchler DA, Kinsella TJ. A retrospective review of nodal treatment for vulvar cancer. Am. J Clinical Oncology 16:38-42, 1993.

113. Sindelar WF, Kinsella TJ, Tepper JE, DeLaney TF, Maher MM, Smith R, Rosenberg SA, Glatstein E. Randomized trial of intraoperative radiotherapy in carcinoma of the stomach. Amer J Surgery 165:178-187, 1993.

114. Petereit D, Mehta M, Turski P, Levin A, Strother C, Mistretta C, Mackie TR, Gehring M, Kubsad S, Kinsella T. Treatment of arteriovenous malformations with stereotactic radiosurgery employing both magnetic resonance angiography and standard angiography as a database. Int J Radiat Oncol Biol Phy 25:309-313, 1993.

115. Sindelar WF, Kinsella TJ, Chen PW, Delaney TF, Tepper JE, Rosenberg SA, Glatstein E. Intraoperative radiotherapy in retroperitoneal sarcomas: Final results of a prospectively randomized clinical trial. Arch Surg 128:402-410, 1993.

116. Mehta M, Petereit D, Turski P, Gehring M, Levin A, Kinsella T. Magnetic resonance angiography: A three-dimensional database for assessing arteriovenous malformations. J Neurosurgery 79:289-293, 1993.

117. Bastin K, Buchler D, Stitt J, Shanahan T, Pola Y, Paliwal B, Kinsella T. Resource utilization: High dose rate versus low dose rate brachytherapy for gynecologic cancer. Am J Clin Oncol 16:256-263, 1993.

118. Bastin KT, Mehta MP, Kinsella TJ. Thoracic volume radiation sparing following endobronchial brachytherapy. Int J Radiat Oncol Biol Phys 25:703-707, 1993.

119. Harari PM, Contreras L, Pickart MA, Ritter MA, Kinsella TJ. Modulation of proliferation kinetics in human squamous cell carcinomas of the head and neck. Arch Otolaryngology Head and Neck Surgery 119:738-742, 1993.

120. Mackie TR, Holmes T, Swerdloft S, Reckwerdt P, Paliwal B, Kinsella T. Tomotherapy: A new concept for delivery of conformal radiotherapy using dynamic compensation. Medical Physics 20:1709-1719, 1993.

121. Horowitz ME, Kinsella TJ, Wexler LH, Belasco J, Triche T, Tsokos M, Steinberg SM, McClure L, Glatstein E, Pizzo PA, Miser JE. Total body irradiation and autologous bone marrow transplant in the treatment of high risk Ewing's sarcoma and rhabdomyosarcoma. J Clinical Oncology 11:1911-1918, 1993.

122. Urtasun RC, Cosmatos D, DelRowe J, Kinsella TJ, Lester S, Wasserman T, Allalunis-Turner J, Fulton D: Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant gliomas. A comparison of short versus long intravenous dose schedules (RTOG 86-12). Int J Radiat Oncol Biol Phys 27:207-214, 1993.

123. Kunugi KA, Lindstrom MJ, Kinsella TJ: Effects of bleomycin with iododeoxyuridine, 5'-amino-5'-deoxythymidine and radiation in a human bladder cancer cell line. Radiat Res 135:262-268, 1993.

124. Lindstrom MJ, Kunugi K, Kinsella TJ. Global comparison of radiation and chemotherapy dose response curves with a test for interaction. Radiat Res 135:269-277, 1993.

Peer-Reviewed Manuscripts (continued)

125. McGinn CJ, Harari PM, Fowler JF, Ford CN, Pyle GM, Kinsella TJ. Dose intensification in curative head and neck cancer: radiotherapy-radiobiological principles and preliminary clinical results. Int J Radiat Oncol Biol Phys 27:363-370, 1993.

126. Petereit DG, Mehta MP, Buchler DA, Kinsella TJ. Inguinofemoral radiation of N_0, N_1, vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used. Int J Radiat Oncol Biol Phys 27:963-967, 1993.

127. Holmes M, Mackie TR, Sohn W, Reckwerdt PJ, Kinsella TJ, Bielajew AF, Rogers DWO. The application of correlated sampling to the computation of electron beam dose distributions in heterogeneous phantoms using the Monte Carlo method. Phys Med Biol 38:675-688, 1993.

128. Petereit DG, Harari PM, Contreras L, Pickart MA, Verma AK, Gerner EW, Kinsella TJ. Combining polyamine depletion with radiation therapy for rapidly dividing head and neck tumors: strategies for improved locoregional control. Int J Radiat Oncol Biol Phys 28:891-898, 1994.

129. Rodriguez R, Ritter MA, Fowler JF, Kinsella TJ. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines *in vivo*. Int J Radiat Oncol Biol Phys 29:105-113, 1994.

130. Ritter MA, Fowler JF, Kim Y, Gilchrist KW, Morrissey LW, Kinsella TJ. Tumor cell kinetics using two labels and flow cytometry. Cytometry 16:49-58, 1994.

131. Kinsella TJ, Kunugi KA, Vielhuber K, McCulloch W, Liu S-H, Cheng Y-C. *In Vivo* comparison of oral 5-Iodo-2'-deoxyuridine and 5-Iodo-2-pyrimidinone-2'-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and a human colon cancer xenograft (HCT-116). Cancer Res 54:2695-2700, 1994.

132. Chi K-H, Kunugi KA, Kinsella TJ. Iododeoxyuridine Chemosensitization of cis-Diamminedichloroplatinum (II) in Human Bladder Cancer Cells. Cancer Res 54:2701-2706, 1994.

133. Ritter MA, Albrechtson JL, Kim YJ, Kinsella TJ. Tumor cell kinetics in mixed populations. Cytometry 16:118-128, 1994.

134. Sindelar WF, Tepper JE, Kinsella TJ, Barnes M, DeLuca AM, Terrill R, Matthews D, Anderson WJ, Bollinger BK, Johnstone PAS. Late effects of intraoperative radiation therapy on retroperitoneal tissues, intestine and bile duct in a large animal model. Int J Radiat Oncol Biol Phys 29:781-788, 1994.

135. Johnstone PAS, Sprague M, DeLuca AM, Bacher JD, Hampshire VA, Terill RE, Kinsella TJ, Sindelar WF. Tolerance of vascular grafts to intraoperative radiotherapy in a canine model. Int J Radiat Oncol Biol Phys 29:1015-1025, 1994.

136. Sarkaria JN, Petereit DG, Stitt JA, Hartman T, Chappell R, Thomadsen BR, Buchler DA, Fowler JF, Kinsella TJ. A comparison of the efficacy and complication rates of low-dose-rate (LDR) vs. high-dose-rate (HDR) brachytherapy in the treatment of uterine cervical carcinoma. Int J Radiat Oncol Biol Phys 30:75-82, 1994.

137. DeLuca AM, Johnstone PAS, Ollayos CW, Bacher JD, Terrill RE, Kinsella TJ, Sindelar WF. Tolerance of the bladder to intraoperative radiation in a canine model: A five-year follow-up. Int J Radiat Oncol Biol Phys 30:339-345, 1994.

Peer-Reviewed Manuscripts (continued)

138. Mehta MP, Masciopinto J, Rozental JM, Levin AB, Chappell R, Bastin KT, Miles J, Turski P, Kubsad SS, Mackie TR, Kinsella TJ. Stereotactic radiosurgery for glioblastoma multiforme: Report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys 30:541-550, 1994.

139. Auchter RM, Mehta MP, Peters NE, Kitchen R, Thomadsen BR, Kinsella TJ. An original technique for surface mold high dose rate brachytherapy for Kaposi's sarcoma. Endocurietherapy/Hyperthermia Oncology 10:193-198, 1994.

140. Sullivan FJ, Herscher LL, Cook JA, Smith J, Steinberg SM, Epstein AA, Mitchell JB, Kinsella TJ, Glatstein E. National Cancer Institute (Phase II) study of high grade glioma treated with partial brain hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 30:583-590, 1994.

141. McGinn CJ, Miller EM, Lindstrom MJ, Kunugi KA, Johnston PG, Kinsella TJ. The role of cell cycle redistribution in radiosensitization: implications regarding the mechanism of fluorodeoxyuridine radiosensitization. Int J Radiat Oncol Biol Phys 30:851-859, 1994.

142. Steeves RA, Stitt JA, Chappell R, Wolberg WH, Kinsella TJ. A simple numerical system for scoring the cosmetic effects of radiation and surgery following conservation therapy for breast cancer. Radiat Oncol Invest 2:194-198, 1994.

143. Noyes WR, Peters NE, Thomadsen BR, Fowler JF, Buchler DA, Stitt JA, Kinsella TJ. Impact of "optimized" treatment planning for tandem and ring and tandem and ovoids using high dose rate brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 31:79-86, 1995.

144. Harari PM, O'Connor NJ, Fiore MC, Kinsella TJ. Radiation oncologists can assist head and neck cancer patients with smoking cessation. Int J Radiat Oncol Biol Phys 31:645-649, 1995.

145. Miller EM, Kunugi KA, Kinsella TJ. Effects of 5'-aminothymidine and leucovorin on the radiosensitization by iododeoxyuridine in human colon cancer cells. Clin Cancer Res 1:407-416, 1995.

146. Terrier P, Henry-Amar M, Triche TJ, Horowitz ME, Terrier-Lacombe MJ, Miser JS, Kinsella TJ, Contesso G, Llombart-Bosch A. Is neuroectodermal differentiation of Ewing's Sarcoma of bone associated with an unfavorable prognosis? A European and American joint study. Eur J Cancer 31A:307-315, 1995.

147. Pestalozzi BC, McGinn CJ, Kinsella TJ, Drake JC, Glennon MC, Allegra CJ, Johnston PG. Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. Brit J Cancer 71:1151-1157, 1995.

148. Kuo M-L, Kunugi KA, Lindstrom MJ, Kinsella TJ. The interaction of hydroxyurea and iododeoxyuridine on the radiosensitivity of human bladder cancer cells. Cancer Res 55:2800-2805, 1995.

149. Schultz CJ, Gaffney DK, Lindstrom M, Kinsella TJ. Iododeoxyuridine radiosensitization of human glioblastoma cells exposed to acute and chronic gamma irradiation: Mechanistic implications and clinical relevance. The Cancer Journal from Scientific American 1:151-161, 1995.

Peer-Reviewed Manuscripts (continued)

150. Sarkaria JN, Mehta MP, Loeffler JS, Buatti JM, Chappell RJ, Levin AB, Alexander E, Friedman WA, Kinsella TJ. Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Int J Radiat Oncol Biol Phys 32:931-942, 1995.

151. Johnstone PAS, DeLuca AM, Bacher JD, Hampshire VA, Terrill RE, Anderson WJ, Kinsella TJ, Sindelar WF. Clinical toxicity of peripheral nerve to intraoperative radiotherapy in a canine model. Int J Radiat Oncol Biol Phys 32:1031-1034, 1995.

152. Noyes WR, Bastin K, Buchler DA, Stitt JA, Thomadsen BR, Fowler JF, Kinsella TJ. Post-operative vaginal cuff radiation using high dose rate afterloading: A phase II clinical protocol. Int J Radiat Oncol Biol Phys 32:1439-1444, 1995.

153. Petereit DG, Sarkaria JN, Chappell R, Fowler JF, Hartmann TJ, Kinsella TJ, Stitt JA, Thomadsen BR, Buchler DA. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 32:1301-1308, 1995.

154. Hoekstra HJ, Sindelar WF, Szabu BG, Kinsella TJ. Hemipelvectomy and intraoperative radiotherapy for bone and soft tissue sarcomas of the pelvic girdle. Radiother Oncol 37:160-163, 1995.

155. Petereit DG, Edwards, SA, Thomadsen B, Fowler J, Buchler D, Stitt JA, Kinsella TJ. Standardized treatment planning for high dose rate brachytherapy to the vaginal cuff. Radiat Oncol Invest 3:196-203, 1995.

156. Johnstone PA, Laskin WB, DeLuca AM, Barnes M, Kinsella TJ, Sindelar WF. Tumors in animals exposed to experimental intraoperative radiotherapy. Int J Radiat Oncol Biol Phys 34:853-858, 1996.

157. Noyes W, Rodriguez R, Knechtle SJ, Pirsch JD, Sollinger HW, D'alessandro AM, Chappell R, Belzer FO, Kinsella TJ. Radiation therapy for renal transplant rejection refractory to pulse steroids and OKT3. Int J Radiat Oncol Biol Phys 34:1055-1059, 1996.

158. Noyes WR, Mulcahy RT, Craig B, Kinsella TJ. The effect of a pure anti-estrogen agent (ICI 182,780) on *in vitro* radiosensitivity of MCF-7 breast carcinoma cells. Rad Onc Investigations 3:232-237, 1996.

159. Auchter RM, Lamond JP, Alexander E, Buatti JM, Chappell R, Friedman WA, Kinsella TJ, Levin AB, Noyes WR, Schultz CJ, Loeffler JS, Mehta MP. A multi-institutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys 35:27-35, 1996.

160. Kinsella TJ, Glennon MC, Kunugi KA, Lindstrom MJ. *In vivo* modulation of 5-iododeoxyuridine metabolism and incorporation into cellular DNA by 5'-amino-5'-deoxythymidine in normal mouse tissues and two human colon cancer xenografts. Clin Cancer Res 2:981-989, 1996.

161. Fowler JF, Kinsella TJ. The limiting radiosensitization of tumors by S-phase sensitizers. Brit J Cancer 74 (Suppl XXVII): S294-S296, 1996.

162. McGinn CJ, Kunugi KA, Tutsch KD, Feierabend C, Alberti D, Lindstrom MJ, Wilding G, Arzoomanian RZ, Kinsella TJ. Leucovorin modulation of iododeoxyuridine radiosensitization: A phase I study. Clin Can Res 2:1299-1305, 1996.

Peer-Reviewed Manuscripts (continued)

163. Lamond JP, Wang M, Kinsella TJ, Boothman DA. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation. Int J Radiat Oncol Biol Phys 36:361-368, 1996.

164. Lamond JP, Wang M, Kinsella TJ, Boothman DA. Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors. Int J Radiat Oncol Biol Phys 36:369-376, 1996.

165. Sharda NN, Kinsella TJ, Ritter MA. Adjuvant radiation vs. observation: A cost analysis of alternative management schemes in early stage testicular seminoma. J Clin Oncol 14:2933-2939, 1996.

166. Urtasun RC, Kinsella TJ, DelRowe J, Farnan N, Lester S, Fulton DS. Survival improvement in anaplastic astrocytoma combining external radiation with halogenated pyrimidines. Final report of RTOG 86-12, Phase I-II study. Int J Radiat Oncol Biol Phys 36:1163-1168, 1996.

167. Kuo M-L, Kinsella TJ. Overexpression of a hexa-histidine and T_7 peptide-tagged human ribonucleotide reductase small subunit, R_2, in Escherichia coli and the generation of human R_2 antibodies. Int. J. of Oncology 10:515-520, 1997.

168. Kuo M-L, Kunugi KA, Lindstrom MJ, Kinsella TJ. The interaction of hydroxyurea and ionizing radiation in human cervical carcinoma cells. The Cancer Journal from Scientific American 3:163-173, 1997.

169. Tannehill SP, Mehta MP, Larson M, Storer B, Pellet J, Kinsella TJ, Schiller J. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small cell lung cancer: Results of a Phase II trial. J Clin Oncol 15:2850-2857, 1997.

170. Mehta M, Noyes W, Craig B, Lamond J, Auchter R, French M, Johnson M, Levin A, Badie B, Robins I, Kinsella T. A cost-effectiveness and cost-utility analysis of radiosurgery versus resection for single brain metastases. Int. J. Radiat. Oncol Biol Phys 39:445-454, 1997.

171. Boothman DA, Burrows H, Yang C-R, Davis TW, Wuerzberger SM, Planchon SM, Odegaard E, Lewis JE, Pink J, Meyers M, VanPatten C, Sharda N, Kinsella TJ. Damage sensing mechanisms in human cells after ionizing radiation. Stem Cells 15: 27-42, 1997.

172. Kinsella TJ, Kunugi KA, Vielhuber KA, Fowler J, Fitzsimmons M, Collins JM. Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose (IPdR) as a prodrug for IUdR-mediated tumor radiosensitization in mouse and human tissues. Clin Cancer Res 4:99-109, 1998.

173. Davis TW, Wilson-Van Patten C, Meyers M, Kunugi KA, Cuthill S, Reznikoff C, Garces C, Boland CR, Kinsella TJ, Fishel R, Boothman DA. Defective expression of the DNA mismatch repair protein, hMLH1, alters G_2/M cell cycle checkpoint arrest following ionizing radiation. Cancer Res 58: 767-778, 1998.

174. Kuo M-L, Kinsella TJ. Expression of ribonucleotide reductase following ionizing radiation in human cervical carcinoma cells. Cancer Res 58: 2245-2252,l998.

175. Forrest LJ, Mahler PA, Vail DM, Mackie TR, Ladd WM, Kinsella TJ. Computed tomographic evaluation of radiation pneumonitis in a canine model. Radiat Oncol Invest 6:128-134, 1998.

Peer-Reviewed Manuscripts (continued)

176. Bullen R, Larson PO, Landeck AE, Nychay S, Snow SN, Hazen P, Kinsella TJ, Lamond J. Angiosarcoma of the head and neck managed by a combination of multiple biopsies to determine tumor margin and radiation therapy. Dermatologic Surgery 24: 1105-1110, 1998.

177. Paliwal BR, Ritter MA, McNutt TR, Mackie TR, Thomadsen BR, Purdy JA, Kinsella, TJ. A solid water pelvic and prostate phantom for imaging, volume rendering, treatment planning and dosimetry for an RTOG multi-institutional, 3-D dose escalation study. Int J Radiat Oncol Bio Phys 42: 205-211, 1998.

178. Berry S, Garces CA, Hwang H-S, Kunugi K, Myers M, Davis TW, Boothman DA, Kinsella TJ. The mismatch repair protein hMLH1, mediates 5-substituted halogenated thymidine analog cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells. Cancer Res 59: 1840-1845, 1999.

179. Yang C-R, Yeh S, Leskov K, Odegaard E, Hsu H-L, Chang C, Kinsella TJ, Chen DJ, Boothman DA. Isolation of Ku70 - Binding Proteins (KUB's). Nucleic Acids Research 27: 2165-2174, 1999.

180. Mineishi S, Longo WL, Atkinson ME, Smith EP, Hamielec M, Wiersma SR, Kinsella TJ, Schuening FG. Addition of high-dose Ara-C to the BMT conditioning regimen reduced leukemia relapse without an increase in toxicity. Bone Marrow Transplantation 23:1217-1222, 1999.

181. Hwang H-S, Davis TW, Houghton JA, Kinsella TJ. Radiosensitivity of thymidylate synthase deficient human colon cancer cells is affected by progression through the G_1 restriction point into S-phase: implications for fluoropyrimidine radiosensitization. Cancer Res 60:92-100, 2000.

182. Kinsella TJ, Vielhuber KA, Kunugi KA, Schupp J, Davis TW, Sands H. Pre-clinical toxicity, pharmacology and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose (IPdR) as a prodrug for IUdR-radiosensitization in U251 human glioblastoma xenografts. Clin Cancer Research 6:1468-1475, 2000.

183. Yang C-R, Leskov K, Hosley-Eberlein K, Criswell T, Pink JJ, Kinsella TJ, Boothman DA. Nuclear Clusterin/XIP8, an x-ray inducible Ku70-binding protein that signals cell death. Proc Natl Acad Sci., USA, 97:5907-5912, 2000.

184. Ellis R, Wu J, Sajja R, Murphy C, Rustgi S, Mackay W, Resnick M, Kinsella TJ. Comparison of a 3D treatment planning computer-based vs. nomogram-based implant technique for prostate carcinoma. J of Brachytherapy 16:55-61, 2000.

185. McGinn CJ, Pestalozzi BC, Drake JC, Glennon MC, Kunugi K, Otterson G, Allegra CJ, Johnston PG, Kinsella TJ. Cell cycle regulation of the G_0/G_1 transition in 5-Fluorouracil-sensitive and resistant human colon cancer cell lines. The Cancer Journal from Scientific America 6:334-342, 2000.

186. Kinsella TJ, Schupp JE, Davis TW, Berry SE, Hwang H-S, Warren K, Balis F, Barnett J, Sands H. Pre-clinical studies of the systemic toxicity and pharmacokinetics of 5-Iodo-2-deoxypyrimidinone-2'-deoxyribose (IPdR) as a radiosensitizing prodrug in two, non-rodent animal species: Implications for Phase I study design. Clin Cancer Res 6:3670-3679, 2000.

187. Berry SE, Davis TW, Schupp JE, deWind N, Kinsella TJ. Selective radiosensitization of drug-resistant, MSH2 mismatch repair-deficient cells by the halogenated thymidine (TdR) analogs; MSH2 mediates TdR analog DNA levels and the differential cytotoxicity and cell cycle effects of TdR analogs and 6-TG. Cancer Res 60:5773-5780, 2000.

Peer-Reviewed Manuscripts (continued)

188. Ellis RJ, Sodee DB, Spirnak JP, Dinchman KH, O'Leary AW, Samuels MA, Resnick MI, Kinsella TJ. Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy. Int J Radiat Oncol Biol Phys 48:683-687, 2000.

189. Abraham D., Colussi, V, Shina, D, Kinsella T, Sibata C. TBI treatment planning using the ADAC Pinnacle treatment planning system. Medical Dosimetry 25:219-224, 2000.

190. Ellis RJ, Kim EY, Conant R, Sodee B, Spirnak JP, Dinchman KH, Beddar S, Wessels B, Resnick MI, Kinsella TJ. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys 49:1281-1286, 2001.

191. Taverna P, Liu L, Hwang H-S, Hanson AJ, Kinsella TJ, Gerson SL. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutation Research 485:269-281, 2001.

192. Myers M, Hwang H-S, Altose BR, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61:5193-5201, 2001.

193. Beddar AS, Kinsella TJ, Ikhlef A, Sibata CH. A miniature "scintillator-fiberoptic-PMT" detector system for the dosimetry of small fields in stereotactic radiosurgery. IEEE Transactions on Nuclear Science 48:924-928, 2001.

194. Yan T, Schupp JE, Hwang H-S, Wagner MW, Strickfaden S, Veigl ML, Sedwick D, Boothman DA, Kinsella TJ. Loss of DNA mismatch repair imparts defective cdc2 signaling and G2 arrest responses without altering survival after ionizing radiation. Cancer Res 61:8290-8297, 2001.

195. Colussi VC, Beddar AS, Kinsella TJ, Sibata CH. *In vivo* dosimetry using a single diode for megavoltage photon beam radiotherapy: Implementation and response characterization. J App Clin Med Phys 2:210-218, 2001.

196. Leskov KS, Klokov DY, Li J., Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 278:11590-11600, 2003.

197. Taverna P, Hwang H-S, Schupp JE, Radivoyevitch T, Session NN, Reddy G, Zarling D, Kinsella TJ. Inhibition of base excision repair potentiates iododeoxyuridine (IdUrd)-induced cytotoxicity and radiosensitization. Cancer Res 63:838-846, 2003.

198. Yan T, Berry SE, Desai AB, Kinsella TJ. DNA mismatch repair (MMR) mediates 6-thioguanine (6-TG) genotoxicity by introducing single strand breaks to signal a G2/M arrest in MMR-proficient RKO cells. Clin Cancer Res 9:2327-2334, 2003.

199. Yamane K, Chen J, Kinsella TJ. Both DNA Topoisomerase II-binding protein 1 and BRCA1 regulate the G2/M cell cycle checkpoint. Cancer Res 63:3049-3053, 2003.

200. Kuo M-L, Hwang H-S, Sosnay PR, Kunugi KA, Kinsella TJ. Overexpression of the R_2 Subunit of Ribonucleotide Reductase in Human Nasopharynogeal Cancer Cells Reduces Radiosensitivity. Cancer J (Boston) 9:277-285, 2003.

201. Berry SE, Loh T, Yan T, Kinsella TJ. Role of MutSα in the recognition of IdUrd in DNA. Cancer Res 63:5490-5495, 2003.

Peer-Reviewed Manuscripts (continued)

202. Ellis RJ, Vertocnik MS, Kim E, Zhou H, Young B, Sodee B, Fu P, Beddar S, Colussi V, Spirnak JP, Dinchman KH, Resnick M, Kinsella TJ. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 57:362-270, 2003.

203. Wu QJ, Chankong V, Jitprapaikulsarn S, Wessels BW, Einstein DB, Mathayomchan B, Kinsella TJ. Real-time inverse planning for gamma knife radiosurgery. Med Phys 30:2988-2995, 2003.

204. Wu JQ-R, Wessels BW, Einstein DB, Maciunas RJ, Kim EY, Kinsella TJ. Quality of coverage: conformity measures for stereotactic radiosurgery. J Appl Clin Med Phys 4:374-381, 2003.

205. Radivoyevitch T, Schupp JE, Taverna P, Kinsella TJ. The linear-quadratic log-survival radiation dose response model: Confidence ellipses, drug-drug interactions and brachytherapeutic gains. Medical Hypotheses and Research 1:23-28, 2004.

206. Yamane K, Yan T, Taylor K, Kinsella TJ. Mismatch repair-mediated G2/M arrest by 6-thioguanine involves the ATR-Chk1 pathway. Biochem Biophys Res Comm 318:297-302, 2004.

207. Wu QJ, Jitprapaikulsarn S, Mathayomcham B, Einstein D, Maciunas RJ, Pillai K, Wessels BW, Kinsella TJ, Chankong V. Clinical evaluation of a gamma knife inverse planning system. Radiosurgery 5:260-266, 2004.

208. Schultz CA, Mehta MP, McGinn CJ, Robins HA, Badie B, Volkman J, Binger D, Alberti D, Feierbend C, Tutsch KD, Wilding G, Kinsella TJ. Continuous 28 day iododeoxyuridine (IUdR) infusion and hyperfractionated accelerated radiotherapy (HART) for malignant glioma: A phase I clinical study. Int J Radiat Oncol Biol Phys 59:1107-1115, 2004.

209. Yan T, Desai AB, Jacobberger JW, Sramroski RM, Loh T, Kinsella TJ. CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses. Mol Cancer Ther 9:1147-1157, 2004.

210. Kunos CA, Resnick M, Kinsella T, Ellis RJ. Seed migration of implanted radioactive seeds for adenocarcinoma of the prostate using a MICK applicator. Brachytherapy 3:71-77, 2004.

211. Seo Y, Yan T, Schupp JE, Colussi V, Taylor KL, Kinsella TJ. Differential radiosensitization in DNA mismatch repair proficient and deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2'-deoxyribose. Clin Cancer Res 10:7520-7528, 2004.

212. Chvetsov AV, Calvetti D, Sohn JW, Kinsella TJ. Regularization of inverse planning for intensity-modulated radiotherapy, Medical Physics 32 (2):501-514, 2005.

213. Yamane K, Kinsella TJ. Casein kinase 2 regulates both apoptosis and the cell cycle following DNA damage induced by 6-thioguanine. Clin Cancer Res 11:2355-2363, 2005.

214. Yamane K, Kinsella TJ. CK2 inhibits apoptosis and changes its cellular localization following ionizing radiation. Cancer Res 65:4362-4367, 2005.

215. Seo Y, Yan T, Schupp JE, Radivoyevitch T., Kinsella TJ. Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as an *in vivo* radiosensitizer in U251 human glioblastoma xenografts. Clin Cancer Res 11:7508-7515, 2005.

Peer-Reviewed Manuscripts (continued)

216. Kunos C., Latson M.S., Overmoyer B., Silverman P., Shenk R., Kinsella T.J., Lyons J. Breast conservation surgery achieving ≥ 2mm tumor-free margins results in decreased loco-regional recurrence rates. The Breast Journal 12:28-36, 2006.

217. Seo Y, Yan T, Schupp JE, Yamane K, Radivoyevitch T, Kinsella TJ. The interaction between two radiosensitizers: 5-iododeoxyuridine and caffeine. Cancer Res 66:490-498, 2006.

218. Talamonti MS, Small W Jr, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, Zacupski MM, Hoffman JP, Freedman GM, Kinsella TJ, Philip PA, McGinn CJ. A multi-institutional phase II trial of preoperative full dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic cancer. Annals Surg Oncology 13:1-9, 2006.

219. Yan T, Seo Y, Schupp JE, Desai AB, Kinsella TJ. Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence. Molecular Cancer Therapeutics 5:893-902, 2006.

220. Kunos C, Colussi V, Getty P, Kinsella TJ. Intraoperative electron radiotherapy for extremity sarcomas does not increase acute or late morbidity. Clinical Orthopedics and Related Research 446:247-252, 2006.

221. Turner DP, Cortellino S, Schupp JE, Loh T, Kinsella TJ, Bellacosa A. The DNA N-glycosylase MED1 exhibits preference for halogenated pyrimidines and is involved in the cytotoxicity of 5-iododeoxyuridine. Cancer Res 66:7686-7693, 2006.

222. Zeng X, Yan T, Schupp JE, Seo Y, Kinsella TJ. DNA mismatch repair initiates 6-thioguanine-induced autophagy through p53 activation in human tumor cells. Clin Cancer Res 13:1315-1321, 2007.

223. Yamane K, Schupp JE, Kinsella TJ. BRCA1 activates a G2/M cell cycle checkpoint by 6-TG-induced DNA mismatch damage. Cancer Res 67:6286-6292, 2007.

224. Kinsella TJ, Kinsella MT, Seo Y, Berk G. 5-iodo-2-pyrimidinone-2'-deoxyribose (IPdR)-mediated cytotoxicity and radiosensitization in U87 human glioblastoma xenografts. Int J Radiat Oncol Biol Phys 69:1254-1261, 2007.

225. Gurkan E, Schupp JE, Azhar MA, Kinsella TJ, Loparo KA. Probabilistic modeling of DNA mismatch repair (MMR) effects on cell cycle dynamics and iododeoxyuridine (IUdR)-DNA incorporation: Implications for targeting MMR-deficient tumors for IUdR-mediated radiosensitization. Cancer Res 67:10993-11000, 2007.

226. Kinsella TJ, Kinsella MT, Hong SW, Johnson JP, Burback B, Tosca PJ. Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2' deoxyribose (IPdR) x 28 days in Fischer-344 rats: Impact on initial phase I trial design of IPdR-mediated radiosensitization. Cancer Chemotherapy and Pharmacology 61:323-334, 2008.

227. Small W Jr., Berlin J, Freeman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarty AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ. Full-dose gemcitabine with concurrent radiation therapy in patients with non-metastatic pancreatic cancer: A multicenter phase II trial. Journal of Clinical Oncology 26:942-947, 2008.

228. Zeng X, Kinsella TJ. Mammalian target of rapamycin and S6 kinase 1 positively regulate 6-thioguanine induced autophagy. Cancer Res 68:2384-2390, 2008.

Peer-Reviewed Manuscripts (continued)

229. Williams CP, Reynolds H, Delaney CP, Champagne B, Obias V, Joh V-G, Merlino J, Kinsella TJ. Clinical results of intraoperative radiotherapy for locally recurrent and advanced tumors with colorectal involvement. Amer J Surgery 195:308-312, 2008.

230. Messick C, Hardacre JM, McGee MF, Siegel CT, Stellato TA, Sanabria JR, Kinsella TJ, Schulak JA. Early experience with intraoperative radiotherapy in resected pancreatic adenocarcinoma. Amer J Surgery 195:405-409, 2008.

231. Kunos CA, Dobbins DC, Kullasekere R, Latimer B, Kinsella TJ. Comparison of helical tomotherapy versus conventional radiation to deliver craniospinal radiation therapy. Technology in Cancer Research and Treatment 7:227-234, 2008.

232. Kinsella TJ, Seo Y, Willis J, Stellato TA, Siegel CT, Harpp D, Willson JK, Gibbons J, Sanabria JR, Hardacre JM, Schulak JA. The impact of resection margin status and post-operative serum CA19-9 levels on survival and patterns of recurrence following post-operative high-dose radiotherapy with 5FU-based concurrent chemotherapy for resectable pancreatic cancer. American Journal of Clinical Oncology, 31:446-453, 2008.

233. Aziz MA, Schupp JE, Kinsella TJ. Modulation of the activity of methyl binding domain protein 4 (MBD4/MED1) while processing iododeoxyuridine generated DNA mispairs. Cancer Biology and Therapy, 8:37-44, 2009.

234. Zagar TM, Shenk RR, Kim JA, Harpp D, Kunos CA, Abdul-Karim FW, Chen WC, Seo Y, Kinsella TJ. Radiation therapy in addition to gross total resection of retroperitoneal sarcoma results in prolonged survival: results from a single institutional study. Journal of Oncology, 2009. Published on-line 1/29/09; PMID 19277103.

235. Seo Y, Kinsella MT, Reynolds HL, Chipman G, Remick SC, Kinsella TJ. The outcome of chemoradiotherapy with 5-fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int. J Radiat Oncol Biol Phys, 75: 143-149, 2009.

236. Seo Y, Kinsella TJ. Essential Role of DNA Base Excision Repair on Survival in an Acidic Tumor Microenvironment. Cancer Res, 69: 7285-7293, 2009.

237. Yan T, Seo Y, Kinsella TJ. Differential cellular responses to prolonged low dose rate ionizing radiation in MLH1-proficient and-deficient colorectal cancer HCT116 cells. Clin Cancer Res 15: 6912-6920, 2009.

238. Kunos CA, Chiu S-M, Pink J, Kinsella TJ. Modulating radiation resistance by inhibiting ribo-nucleotide reductase in cancers with virally-or mutationally-silenced p53 protein. Radiation Res 172: 666-676, 2009.

239. Kunos CA, Waggoner S, von Gruenigen V, Eldermire E, Pink J, Dowlati A, Kinsella TJ. Phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in combination with pelvic radiation therapy and weekly cisplatin chemotherapy for locally advanced cervical cancer. Clin Cancer Research 16: 1298-1306, 2010.

240. Zeng X, Kinsella TJ. BNIP3 is essential for mediating 6-thioguanine-induced autophagy following DNA mismatch repair processing. Cell Research 20: 665-75, 2010.

Peer-Reviewed Manuscripts (continued)

241. Kunos C, Radivoyevitch T, Pink J, Chin SM, Stefan T, Jacobberger J, Kinsella TJ. Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat Res 174: 574-81, 2010.

242. Du W, Kinsella TJ. A rapid, simple DNA mismatch repair substrate construction method. Frontiers in Oncology, doi: 10.3389/fonc.2011.0008, published on line 6/6/11.

243. Kinsella TJ, Baron ED, Colussi VC, Cooper KD, Hoppel CL, Ingalls ST, Kenney ME, Li X, Oleinick NL, Stevens SR, Remick, SC. Preliminary clinical and pharmacologic investigation of photodynamic therapy with the silicon phthalocyanine photosensitizer, Pc-4, for primary or metastatic skin cancer. Frontiers in Oncology, doi: 10.3389/fonc.2011.00014, published on line, 6/30/11.

244. Kinsella TJ, Gurkan-Cavusoglu E, Loparo KA. Integration of principles of systems biology and radiation biology: Toward development of *in silico* models to optimize IUdR-mediated radiosensitization of DNA mismatch repair-deficient (damage tolerant) human cancers. Frontiers in Oncology, doi: 10.3389/fonc.2011.00020, pp.141-144, published on line 8/10/11.

245. Gurkan-Cavusoglu E, Schupp JE, Kinsella TJ, Loparo KA. Analysis of cell cycle dynamics using probabilistic cell cycle models. Proceedings of 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Boston, MA, August, 2011.

246. Zeng X, Kinsella TJ. Impact of autophagy on the efficacy of chemotherapy and radiotherapy mediated tumor cytotoxicity: "To live or not to live". Frontiers in Oncology, doi: 10.3389/fonc.2011.00030, published on line 10/3/11.

247. Chapman TR, Kinsella TJ. Ribonucleotide reductase inhibitors: A new look at an old target for radiosensitization. Frontiers in Oncology, doi 10.3389/fonc.2011-0056, published on line 1/4/2012.

248. Gurkan-Cavusoglu E, Avadan S, Liu L, Loparo KA, Kinsella TJ. Developing an *in silico* model of the modulation of base excision repair (BER) using methoxyamine for more targeted cancer therapeutics. IET Systems Biology, 2012 (submitted).

249. Gurkan-Cavusoglu E, Schupp JE, Kinsella TJ, Loparo KA. Quantitative analysis of the effects of combined iododeoxyuridine (IUdR) and ionizing radiation treatment on the cell cycle dynamics of DNA mismatch repair deficient cells using probabilistic cell cycle models. IEEE Transactions on Biomedical Engineering, 2012 (submitted).

250. Jeyapalan S, Boxerman J, Donahue J, Goldman M, Kinsella, TJ, DiPetrillo T, Evans D, Elinzano H, Constantinou M, Stopa E, Puthawala MY, Cielo D, Santaniello A, Oyelese A, Rosati K, Isdale D, Safran H. Paclitaxel poliglumex, temozolomide and radiation for newly diagnosed high-grade glioma: A Brown University Oncology Group phase II study. Amer J Clin Oncol, 2012 (submitted).

Invited Papers, Editorials, Book Chapters, Letters to the Editor:

1. Kinsella TJ, Bloomer WD. Primary radiation therapy for breast cancer. Female Patient 5:60-67, 1980.

2. Kinsella TJ, Weichselbaum RR, Sheline G. Radiation injury of cranial and peripheral nerves. In: Radiation Damage to the Nervous System: Delayed Therapeutic Hazards, Gilbert H and Kagan R, eds, New York: Raven Press, 1980, pp 145-151.

3. Kinsella TJ, Bloomer WD. Current developments--new therapeutic strategies in radiation therapy. JAMA 245:1669-1674, 1981.

4. Kinsella TJ, Fraass BA, Glatstein E. Late effects of radiation therapy in the treatment of Hodgkin's disease. Cancer Treatment Reports 66:991-1002, 1982.

5. Kinsella TJ. The role of combined modality therapy in the curative management of advanced stage "favorable" non-Hodgkin's lymphomas. Cancer Treatment Reports 66:421-425, 1982.

6. Kinsella TJ, Glatstein E. Staging laparotomy and splenectomy for Hodgkin's disease: current status. Cancer Investigation 1:87-91, 1983.

7. Kinsella TJ, Glatstein E. Management of acute and late effects of radiation therapy on normal tissues. In: Supportive Care of the Cancer Patient, Wiernik PH, ed, Futura Publishing Company, 1983, pp 325-348.

8. Kinsella TJ. The role of radiation therapy alone and combined with infusional chemotherapy for treating liver metastases. Seminars in Oncology 10:215-222, 1983.

9. Kinsella TJ. Early intervention with combined modality therapy for "favorable" non-Hodgkin's lymphomas of advanced stage. In: Lymphomas II. Bennett JM, ed, Boston: Martinus Nijhoff, 1983, pp 272-287.

10. Brown JM, Biaglow JE, Hall EJ, Kinsella TJ, Phillips TL, Urtasun RC, Utley JF, Yuhas JM. Sensitizers and protectors to radiation and chemotherapeutic drugs. Cancer Treatment Symposia 1:85-103, 1984.

11. Carney DN, Brower M, Morstyn G, Mitchell JB, Kinsella TJ. Clinical and laboratory sensitivity of human lung cancer to chemotherapy and irradiation: correlation with endocrine properties. In: The Endocrine Lung in Health and Disease, Becker KL and Gazdar AF, eds, Philadelphia: WB Saunders Co., 1984, pp 603-611.

12. Kinsella TJ, Lichter AS, Miser J, Gerber, L. Glatstein E. Local treatment of Ewing's sarcoma: radiation therapy versus surgery. Cancer Treatment Reports 68:695-701, 1984.

13. Kinsella TJ, Mitchell JB, Russo A, Morstyn G, Glatstein E. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: nonhypoxic cell sensitizers. Int J Rad Oncol Biol Phys 10:1399-1406, 1984.

14. Kinsella TJ, Sindelar WF. Intraoperative radiation therapy. In: Principles and Practice of Oncology, 2nd edition, DeVita VT, Hellman S, Rosenberg SA, eds, Lippincott, 1985, pp 2293-2304.

15. Sindelar WF, Kinsella TJ, Mayer R. Pancreatic cancer. In: Principles and Practice of Oncology, 2nd edition, DeVita VT, Hellman S, Rosenberg SA, eds, Lippincott, 1985, pp 691-741.

Invited Papers, Editorials, Book Chapters, Letters to the Editor (continued)

16. Myers CE, Kinsella TJ. Pulmonary toxicity. In: Principles and Practice of Oncology, 2nd edition, DeVita VT, Hellman S, Rosenberg SA, eds, Lippincott, 1985, pp 2022-2032.

17. Russo A, Mitchell J, Kinsella T, Morstyn G, Glatstein E. Determinants of radiosensitivity. Seminars in Oncology 12:332-349, 1985.

18. Kinsella TJ, Glatstein E, Sindelar WF. Intraoperative radiotherapy. Hospital Practice 20:125-141, 1985.

19. Mitchell JB, Russo A, Kinsella TJ, Glatstein E. The use of nonhypoxic cell sensitizers in radiobiology and radiotherapy. Int J Rad Oncol Biol Phys 12:1513-1518, 1986.

20. Kinsella TJ. Limited surgery and radiation therapy for sarcomas of the hand and foot. Int J Rad Oncol Biol Phys 12:2045-2046, 1986.

21. Sindelar WF, Kinsella TJ. Intraoperative radiotherapy in carcinoma of the stomach. In: Stomach Cancer, Gall FP, Hermanek P, Hornig D, eds, Munich: Springer Verlag, 1986, pp 128-140.

22. Kinsella TJ, Sindelar WF, Bloomer WD. Radiation enteritis: pathophysiology, clinical manifestations and management. In: Surgery of the Small Intestine, Nyhus LM, Nelson RL, eds, Norwalk, Connecticut: Appleton-Century-Crofts, 1987, pp 193-203.

23. Kinsella, TJ, Sindelar WF, Tepper JE, Tochner Z, Rich TA. Intraoperative radiotherapy. In: Innovations in Radiation Oncology Research, Peters LJ and Withers R, eds, Springer-Verlag, 1987, pp 141-152.

24. Sindelar WF, Kinsella TJ. Intraoperative radiotherapy: the National Cancer Institute experience. In: Progress in Radio-Oncology, volume 3, Karcher H, ed, New York: Raven Press, 1987, pp 141-152.

25. Hoekstra HJ, Sindelar WF, Kinsella TJ, Oldhoff J. History, preliminary results, complications and future prospects of intraoperative radiotherapy. J Surg Oncol 36:175-182, 1987.

26. Stea B, Kinsella TJ. Superior vena cava syndrome: an oncologic emergency. In: Thoracic Oncology, Roth J, Ruckdeschel J, Weisenburger T, eds, Philadelphia: W.B. Saunders, 1988, pp 280-292.

27. Brown JM, Hall EJ, Hirst DG, Kinsella TJ, Kligerman MM, Mitchell JB, Travis EJ. Valeriote F: Chemical modification of radiation and chemotherapy. Am J Clin Oncol 11:288-303, 1988.

28. Kinsella TJ. Adjuvant radiotherapy in pancreatic carcinoma-A reappraisal. Cancer Investigation 6:745-746, 1988.

29. Kinsella TJ. Future approaches in radiation therapy. In: New Directions in Cancer Treatment, Magrath I, ed, New York: Springer Verlag, 1988, 31-52.

30. Miser J, Triche T, Pritchard D, Kinsella T. Ewing's sarcoma and the nonrhabdomyosarcoma soft tissue sarcomas of childhood. In: Principles and Practices of Pediatric Oncology, Pizzo P and Poplack D, eds, Philadelphia:Lippincott, 1989, pp 659-688.

31. Israel MA, Miser J, Triche T, Kinsella TJ. Neuroepithelial tumors. In: Principles and Practice of Pediatric Oncology, Pizzo P and Poplack D, eds, Philadelphia: Lippincott, 1989, 623-634.

32. Brennan MF, Kinsella TJ, Friedman M. Pancreatic cancer. In: Principles and Practice of Oncology, 3rd edition, DeVita VT, Hellman S, Rosenberg SA, eds, Lippincott, 1989, 800-835.

Invited Papers, Editorials, Book Chapters, Letters to the Editor (continued)

33. Sindelar WF, Kinsella TJ. Intraoperative radiation therapy for locally advanced cancers. Southern Med J 82:358-363, 1989.

34. Kinsella TJ. Effects of radiation therapy and chemotherapy on testicular function. Prog Clin Biol Res 302:157-171, 1989.

35. Paliwal BR, Fowler JF, Herbert DE, Kinsella TJ, Orton CG. Prediction of response in radiation therapy, Part I - The physical and biological basis and Part II - Analytical models and modeling. Published by the American Institute of Physics, Inc., New York, NY, 1989.

36. Kinsella TJ. Treatment approaches in soft tissue sarcomas -- putting our best foot forward. Int J Radiat Oncol Biol Phys 19:499-501, 1990.

37. Kinsella TJ, Sindelar WF. Normal tissue tolerance to intraoperative radiation therapy (IORT)--experimental and clinical studies. In: Frontiers in Radiation Therapy and Oncology: Radiation Effects and Tolerance of Normal Tissue, Volume 23, Vaeth J, ed, Karger Basal Switzerland, 1990, pp. 202-214.

38. NIH Consensus Conference. (Kinsella TJ; contributing author) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990.

39. Mahler P, Kinsella TJ. Radiation and cytotoxic drug effects on lung natural defense mechanisms. In: Respiratory Disease in the Immunosuppressed Host, Shelhamer J, Pizzo P, Parrillo J, Masur H (eds), Philadelphia, J.B. Lippincott, 1991, pp. 30-36.

40. Kinsella TJ, Gould MN, Mulcahy RT, Ritter MA, Fowler JF. Integration of cytostatic agents and radiation therapy: A different approach to "proliferating" human tumors. Int J Radiat Oncol Biol Phys 20:295-302, 1991.

41. Rodriquez R, Kinsella TJ. Sarcoma: Combined modality approaches. In: Current Therapy in Hematology/Oncology - 4, Brain MC, Carbone PP (eds), Philadelphia, B.C. Decker, 1991, pp. 377-380.

42. Rozental JM, Kinsella TJ. Brain tumors. In: Combined Modality Cancer Therapy: Radiation and Infusional Chemotherapy. Lokich J, Byfield J (eds), Chicago, Precept Press, Inc., 1991, pp. 215-239.

43. Giese WL, Kinsella TJ. Radiation injury to peripheral and cranial nerves. In: Radiation Injury to the Nervous System, 2nd edition, Gutin P, Sheline G, Liebel S, eds, New York, Raven Press, 1991, pp. 383-403.

44. Kinsella TJ. Radiosensitization of nonhypoxic cells. In: Concomitant Continuous Infusion Chemotherapy and Radiation. Rotman M, Rosenthal CJ (eds), Heidelberg-Springer, 1991, pp. 91-96.

45. Stea B, Kinsella TJ. Superior vena cava syndrome: Clinical features, diagnosis, and treatment. In: The Mediastinum, Shields TW (ed), Philadelphia, Lea and Febiger, 1991, pp 350-362.

46. Rodriguez R, Kinsella TJ. Halogenated pyrimidines as radiosensitizers for high grade glioma: Revisited. Int J Radiat Oncol Biol Phys 21:859-862, 1991.

47. McGinn CJ, Kinsella TJ. Combined modality therapy. Current Oncology in Oncology 3: 1049-1054, 1991

Invited Papers, Editorials, Book Chapters, Letters to the Editor (continued)

48. Kinsella TJ. Radiosensitization and cell kinetics: Clinical implications for S-phase specific radiosensitizers. Seminars in Oncology 19:41-47, 1992.

49. McGinn CJ, Kinsella TJ. The experimental and clinical rationale for the use of S-phase specific radiosensitizers to overcome tumor cell repopulation. Seminars in Oncology 19:21-28, 1992.

50. Rodriguez R, Kinsella TJ. Ewing's sarcoma. In: Combined Radiotherapy and Chemotherapy in Clinical Oncology. A. Horowich, Ed., Hodder & Stoughton Publishers, 1992, pp. 203-209.

51. Brennan MF, Kinsella TJ, Casper ES. Cancer of the pancreas. In: Principles and Practice of Oncology, 4th Edition, DeVita VT, Hellman S, Rosenberg SA, eds, Lippincott, 1993, pp. 849-882.

52. Beard CJ, Coleman CN, Kinsella TJ. Radiation sensitizers In: Principles and Practice of Oncology, 4th Edition, DeVita VT, Hellman S, Rosenberg SA, eds, Lippincott, 1993, pp. 2701-2712.

53. Miser JS, Pritchard DJ, Triche TJ, Kinsella TJ. The other soft tissue sarcomas of childhood. In: Principles and Practice of Pediatric Oncology. 2nd edition. P.A. Pizzo and D.G. Poplack, Eds, J.B. Lippincott Company, 1993, pp 823-840.

54. Kinsella TJ: Soft Tissue Sarcoma: Combined Modality Approaches. In: Organ Conservation in Curative Cancer Treatment. Indications, Contraindications, Methods. JL Meyer and JM Vaeth, Eds; Karger, 1993, pp 186-199.

55. Mehta MP, Kinsella TJ. Cavernous sinus cranial neuropathies. Is there a dose-response relationship following radiosurgery? Int J Radiat Oncol Biol Phys 27:477-480, 1993.

56. McGinn CJ, Kinsella TJ. The clinical rationale for S-phase radiosensitization in human tumors. Current Problems in Cancer 27:273-324, 1993.

57. McGinn CJ, Kinsella TJ. Biochemical Modifiers: Nonhypoxic cell sensitizers. In: Radiation Oncology: Technology and Biology, 1st edition, Mauch PM, Loeffler JS, eds, W.B. Saunders, 1994, pp. 90-112.

58. Petereit DG, Fowler JF, Kinsella TJ. Optimizing the dose rate and technique in cervical carcinoma - balancing cases versus complications. Int J Radiat Oncol Biol Phys 29:1195-1198, 1994.

59. Johnstone PAS, Sindelar WF, Kinsella TJ. Experimental and clinical studies of intraoperative radiation therapy. Current Problems in Cancer 28:249-292, 1994.

60. Harari PM, Kinsella TJ. Advances in radiation therapy for head and neck cancer. Current Opinion in Oncology 7:248-254, 1995.

61. Mehta M, Kinsella TJ. Superior vena cava syndrome, In: Thoracic Oncology, 2nd edition, Roth JA, Ruckdeschel JC, Weisenburger TH, eds, Lippincott, 1995, pp. 239-258.

62. Kinsella TJ. Commentary on Radiation Sensitization by Fluorinated Pyrimidines. Oncology 9:14-17, 1995.)

63. Collins JM, Klecker RW, Chang AE, Kinsella TJ. Correspondence RE: J.A. Knol et al, Incorporation of 5-bromo-2'-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion. Cancer Res 55:3687-3691, 1995. Cancer Res 56:2677-2678, 1996.

Invited Papers, Editorials, Book Chapters, Letters to the Editor (continued)

64. Kinsella TJ. An approach to the radiosensitization of human tumors. The Cancer Journal from Scientific American 2:184-193, 1996.

65. Noyes WR, Auchter RM, Craig B, French MC, Johnson MN, Lamond JP, Levin AB, Kinsella TJ, Mehta MP. Cost analysis of radiosurgery versus resection for single brain metastases. In Radiosurgery 1996, Kondziolka D (ed), S. Karger Publishers, 1996, pp 172-179.

66. Kinsella TJ, Sindelar WF. Intraoperative radiotherapy for cancer of the pancreas - experimental and clinical studies. Cancer 78:598-603, 1996.

67. Sharda N, Yang C-R, Kinsella TJ, Boothman D. Radiation Resistance, In: Encyclopedia of Cancer, Volume 10, Bertino JR, ed., Academic Press, Inc., 1997, pp 1409-1419.

68. Miser JS, Triche TJ, Kinsella TJ, Pritchard DJ. Other soft tissue sarcomas of childhood. In: Principles and Practice of Pediatric Oncology, 3rd edition, Pizzo P, and Poplack D, eds, Lippincott, 1997, pp 865-888.

69. Petereit DG, Kinsella TJ. An approach to radiosensitizing cervical cancer using chemical modulators of nucleoside metabolism. Seminars in Radiation Oncology 7:324-334, 1997.

70. Davis TW, Myers M, VanPatten C, Sharda N, Yang C-R, Kinsella TJ, Boothman DA. Transcriptional responses to damage created by ionizing radiation: molecular sensors. In: DNA Damage and Repair. Volume 2: DNA Repair in Higher Eukaryotes. pp 223-261, Nickoloff JA and Hoekstra M, eds., Humana Press 1998.

71. Mehta MP, Kinsella TJ. Treatment of low grade intramedullary gliomas: Biopsy and radiation therapy. In: Controversies in Spine Surgery. Zdeblick TA, Benzel EC, Anderson P, Stillerman CB, eds, Quality Medical Publishers, St. Louis, MO, 1998.

72. Sindelar WF, Hoekstra H, Johnstone PAS, Kinsella TJ. Normal tissue tolerance to intraoperative radiotherapy: The National Cancer Institute Experimental and Clinical Studies In: Intraoperative Irradiation–Techniques and Results. Gunderson LL, Willett CG, Harrison LB, Calvo FA, eds., Humana Press Inc., pp 131-146, 1999.

73. Sindelar WF, Kinsella TJ. Studies of intraoperative radiotherapy in carcinoma of the pancreas. Annals of Oncology 10:supp4:226-230, 1999.

74. Parry EJ, Stevens SR, Gilliam AC, Horvath N, Charif M, Spiro TP, Adler LP, Shina D, Kinsella T, Heyman EN, Cooper KD, Wood GS. On the horizon: Management of cutaneous lymphomas using a multidisciplinary approach. Arch Dermatology 135:907-911, 1999.

75. Dowlati A, Eakin R, Kinsella T. Chemotherapy-radiation interaction in lung cancer. In: Lung Cancer: Principles and Practice of Oncology. Pass H, Mitchell JB, Minna J, Turrissi A eds., 2nd edition; Lippincott, Williams and Wilkins, 2000, pp. 284-303.

76. Ellis RJ, Nag S, Kinsella TJ. Alternative techniques of intraoperative radiotherapy. European Journal of Surgical Oncology 26 (supplement A):S25-27, 2000.

77. Sibata CH, Colussi VC, Oleinick NL, Kinsella TJ. Photodynamic therapy: A new concept in medical treatment. Brazilian Journal of Medical and Biological Research 33:869-880, 2000.

Invited Papers, Editorials, Book Chapters, Letters to the Editor (continued)

78. Miyamoto S, Huang T, Wuerzberger –Davis S, Pink JJ, Tagiarino C, Kinsella TJ, Boothman DA. Cellular and molecular responses to topoisomerase I poisons: Exploiting synergy for improved radiotherapy. Annals of New York Academy of Sciences 922:274-292, 2000.

79. Sibata CH, Colussi VC, Oleinick NL, Kinsella TJ. Photodynamic therapy in oncology. Expert Opin Pharmacother 2:917-927, 2001.

80. Heiner JP, Kinsella TJ, Zdeblick TA, eds. Management of Metastatic Disease to the Musculoskeletal System. Quality Medical Publishing, 2001.

81. Samuels MA, Kinsella TJ. Endocrine cancer In: Management of Metastatic Disease to the Musculoskeletal System. Heiner JP, Kinsella TJ, Zdeblick TA, eds. Quality Medical Publishing 2001, pp. 203-220.

82. Ellis RJ, Kinsella TJ. Radiation therapy-general approaches In: Management of Metastatic Disease to the Musculoskeletal System. Heiner JP, Kinsella TJ, ZdeblickTA, eds. Quality Medical Publishing 2001, pp. 157-166.

83. Beddar AS, Domanovic MA, Kubu ML, Ellis RJ, Sibata CH, Kinsella TJ. Mobile linear accelerators for intraoperative radiation therapy. AORN J 74:700-705, 2001.

84. Berry SE, Kinsella TJ. Targeting DNA mismatch repair for radiosensitization. Seminars in Radiation Oncology 11:300-315, 2001.

85. Leskov KS, Criswell T, Antonio S, Li J, Yang C-R, Kinsella TJ, Boothman DA. When x-ray-inducible proteins meet DNA double strand break repair. Seminars in Radiation Oncology 11:352-372, 2001.

86. Kinsella TJ, McGinn CJ, Guest Editors. New Targets for Tumor Radiosensitization. Seminars in Radiation Oncology 11:269, 2001.

87. Kinsella TJ. Radiation Emergencies In: Oncologic Emergencies; P.G. Johnston and R.A.J. Spence, eds; Oxford University Press 2002; pp. 319-336.

88. Ellis RJ, Kim E, Kinsella TJ, Eisenberg, B. Intraoperative Radiotherapy in the Multimodality Approach to Bone and Soft Tissue Cancers. Surgical Oncology Clinics of North America 12:1015-1029, 2003.

89. Sindelar WF, Kinsella TJ. Normal Tissue Tolerance to Intraoperative Radiotherapy. Surgical Oncology Clinics of North America 12:925-942, 2003.

90. Domanovic MA, Ouzidane M, Ellis RJ, Kinsella TJ, Beddar AS. Using intraoperative radiation therapy—A case study. AORN J 77: 412-417, 2003.

91. Greskovich JF, Kinsella TJ. Superior Vena Cava Syndrome: Clinical Features, Diagnosis, and Treatment. General Thoracic Surgery, 6th Edition. Shields TW et al (ed). Lippincott Williams & Wilkins, 2004, pp.2545-2566.

92. Zarling DA, Vallerga AK, Kinsella T. New radiosensitizing (RS) regimens, drugs, prodrugs and candidates: Capecitabine, Gemcitabine, Fludarabine, IPdR, Avastin, Veglin, Gleevac, Radvac, Erbitux or Irressa. Clinical Advances in Hematology and Oncology 2:793-805, 2004.)

Invited Papers, Editorials, Book Chapters, Letters to the Editor (continued)

93. Kinsella TJ, Sohn J, Wessels BW. Principles of Radiation Oncology in: Oncology: An Evidence Based Approach; Chang AE, Gantz PA, Hayes DF, Kinsella TJ, Pass HI, Schiller J, Stone RM, Strecher V, (eds), Springer-Verlag; New York, New York, pp. 41-57, 2005.

94. Chang AE, Gantz PA, Hayes DG, Kinsella TJ, Pass HI, Schiller J, Stone RM, Strecher V (eds). Oncology: An Evidence Based Approach. Springer-Verlag, New York, New York, 2005.

95. Krishnamurthi SS, Seo Y, Kinsella TJ. Adjuvant therapy for rectal cancer. Clinics in Colon and Rectal Surgery 20:167-181, 2007.

96. Zeng X, Kinsella TJ. A novel role for DNA mismatch repair and the autophagic processing of chemotherapy damage in human tumor cells. Autophagy 3:368-370, 2007.

97. Saif MF, Cheng T-C, Berk G, Kinsella TJ. IPdR: A novel oral radiosensitizer. Expert Opinion in Investigational Drugs 16:1415-1424, 2007.

98. Gurkan E, Schupp JE, Kinsella TJ, Loparo KA. A conceptual modeling framework for the study of DNA mismatch repair pathway to improve therapeutic gain in cancer treatment. Proc. of the IEEE/NIH BISTI 2007 Life Science Systems and Applications Workshop (LISSA 2007), pp. 179-182.

99. Klionsky DJ, Agostinis P, Agrawal DK, et al (including Kinsella TJ). Guidelines for monitoring autophagy in higher eukaryotes. Autophagy 4:1-25, 2008.

100. Small et al (including Kinsella TJ). Response to letter by Drs. Kleeff and Friessto. Full-dose gemcitabine with concurrent radiation therapy in patients with non-metastatic pancreatic cancer: A multicenter phase II trial. J Clin Oncol 26:3100-3101, 2008.

101. Abbas R, Willis J, Kinsella T, Siegel C, Sanabria JR. Primary squamous cell carcinoma of the main hepatic bile ducts: a case report and review of the current literature. Can J Surg, 51:85-86, 2008.

102. Zagar TM, Triche TJ, Kinsella TJ. Extraosseous Ewing's Sarcoma: 25 years later. J Clin Oncol, 26:4230-4231, 2008.

103. Kinsella TJ. Update on radiosensitzation by the halogenated thymidine analogs-molecular mechanisms of drug processing and cell death signaling: Implications for future clinical trials. Cancer Biol and Ther, 7:1567-1569, 2008.

104. Kinsella TJ. Coordination of DNA mismatch repair and base excision repair of chemotherapy and radiation damage for targeting resistant (damage tolerant) cancers. Clin Cancer Res, 15: 1848-1853, 2009.

105. Kinsella TJ. Understanding DNA damage response and DNA repair pathways: Application to more targeted cancer therapeutics. Seminars in Oncology, 36, Suppl 1: S42-S51, 2009.

106. Kinsella TJ. Strategies for targeted cancer therapy involving DNA damage response/repair pathways. American Society of Clinical Oncology Educational Book, pp 138-143, 2009

107. Seo Y, Kinsella TJ. Post-resection CA19-9 value as a prognostic factor: in response to the letter by Kilickap and Arslan. Amer. J. Clin Oncol 33: 107, 2010.

Invited Papers, Editorials, Book Chapters, Letters to the Editor (continued)

108. Kinsella TJ. Radiation Oncology: Today and Tomorrow. Frontiers in Oncology, doi: 10.3389/fonc.2011.00007, published on line 5/27/11.

109. Vujaskovic Z, Willett CG, Tepper JE, Kinsella, TJ, Gunderson LL. Normal Tissue Tolerance to Intraoperative Electron Beam Radiation Therapy (IOERT), External Beam Radiation Therapy (EBRT), or Both: Animal and Clinical Studies in: Intraoperative Irradiation-Techniques and Results. Gunderson LL, Willett CG, Calvo FC, Harrison LB (eds); Second Edition; Springer-Verlag, New York, NY, pp 119-140, 2011.

110. Klionsky DJ, Abdalla FC, Abeliovich H, Kinsella TJ, et.al. Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy. Autophagy 8: 445-544, 2012.

111. Kinsella TJ. DNA Mismatch Repair: It's Role in Human Carcinogenesis and as a Predictive and/or Prognostic Biomarker for Cancer Therapy in: DNA Repair and Cancer: Bench to Clinic. Madhusudan S, Wilson DM (eds), Science Publishers, Enfield, NH, pp 195-229, 2012.

112. Leonard K, Kinsella TJ. The Role of MLH1 in DNA Mismatch Repair. In Encyclopedia of Cancer Therapeutic Targets. J Marshall (ed), First Edition, Springer, New York, NY, (in press).

113. Hepel JT, Kinsella TJ. Osteosarcoma and Other Primary Tumors of Bone. In Principles and Practice of Radiation Oncology. Halperin EC, Wazer DE, Perez CA, Brady LW (eds), 6th Edition, Lippincott, Williams & Wilkins, Philadelphia, PA, (in press).

114. Kinsella TJ. Intraoperative Radiotherapy. In Principles and Practice of Radiation Oncology. Halperin EC, Wazer DE, Perez CA, Brady LW (eds), 6th Edition, Lippincott, Williams & Wilkins, Philadelphia, PA, (in press).